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Abstract 
Hanna Öhman. Immunogenetic risk factors of Chlamydia-induced tubal factor infer-
tility. National Institute for Health and Welfare (THL). Research 85/2012. 135 
pages. Helsinki, Finland 2012. 
ISBN 978-952-245-681-6 (printed); ISBN 978-952-245-682-3 (pdf) 
 
Chlamydia trachomatis is the most common bacterial sexually transmitted disease 
worldwide. In women, persistent or repeated infection can cause tissue damage in 
the Fallopian tubes and impair their normal function, which increases the risk of 
infertility. The T lymphocyte immune response is crucial in the resolution of acute 
infection but T cells also probably play an important role in the pathogenesis of C. 
trachomatis-associated tubal damage.  
The aim of this work was to study how interindividual differences in im-
munoregulatory genes affect the susceptibility to and severity of tubal damage and 
how related genes are associated with C. trachomatis-specific immune responses. 
The study population consisted of 164 infertile women with C. trachomatis-induced 
tubal factor infertility (TFI) and a control group consisting of 176 female blood do-
nors and 179 pregnant women. The study population also included 17 women who 
were infertile for reasons other than TFI. 
The immunosuppressive interleukin IL-10 and its genetic polymorphism 
IL10 -1082 A/G had a strong influence on C. trachomatis-induced cytokine produc-
tion. IL-10 levels also reflected the production of proinflammatory interferon-γ 
(IFN-γ) and tumor necrosis factor (TNF) as well as the intensity of the lymphocyte 
proliferative (LP) response. The IL10 -1082 AA genotype, which was associated 
with low IL-10 production, increased the risk of severe tubal damage in women with 
C. trachomatis-induced TFI. 
A single nucleotide polymorphism (SNP) at +874 A/T in the IFN-γ-coding IFNG 
gene was not associated with disease severity. However, this SNP was associated 
with the intensity of the LP response and the quantitative secretion of IFN-γ was in 
line with the LP responses. The IFNG +874 A/T and IL10 -1082 A/G SNPs were 
found to have a cumulative effect on the intensity of C. trachomatis-induced LP 
responses. In addition, SNPs in TNF- and IL-12-coding genes, TNF -308 A/G and 
IL12B 1188 A/C, were associated with TFI and the severity of tubal damage. How-
ever, their roles in the cytokine profile need to be studied further. 
The results of the present work support the hypothesis that genetic factors con-
tribute to the risk and severity of TFI. Our results suggest that genetic predisposition 
to a strong inflammatory response to C. trachomatis infection may result in severe 
disease manifestation.  
 
Keywords: cell-mediated immune response, Chlamydia trachomatis, cytokines, 
genetic polymorphism, interferon-γ, interleukin-10  
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Tiivistelmä 
Hanna Öhman. Immunogenetic risk factors of Chlamydia-induced tubal factor infer-
tility [Perimän vaikutus immuunivasteen säätelyyn klamydiaperäisen hedelmät-
tömyyden tautimekanismeissa]. Terveyden ja hyvinvoinnin laitos (THL). Tutkimus 
85/2012. 135 sivua. Helsinki, Finland 2012. 
ISBN 978-952-245-681-6 (painettu); ISBN 978-952-245-682-3 (pdf) 
 
Chlamydia trachomatis -bakteerin aiheuttama klamydiainfektio on maailmanlaajui-
sesti yleisin sukupuoliteitse tarttuva bakteeritauti. Naisilla pitkäkestoinen tai toistuva 
infektio voi vaurioittaa munanjohtimia, mikä saattaa johtaa hedelmättömyyteen. 
Soluvälitteistä immuunivastetta tarvitaan tartunnan parantumiseen, mutta se on osal-
lisena myös kudosvaurioiden kehittymisessä. 
Tämän väitöskirjatyön tavoitteena oli selvittää, miten yksilöiden väliset geneetti-
set erot sytokiinien tuotannossa vaikuttavat klamydiaperäisen hedelmättömyyden 
riskiin, kudosvaurioiden vakavuuteen ja soluvälitteisen immuunivasteen voimakkuu-
teen. Tutkimusaineistossa tautitapauksia edustivat 164 lapsettomuushoitoihin hakeu-
tunutta naista, joilla hedelmättömyyden syyksi oli paljastunut munanjohdinvaurio. 
Kontrolleina oli 176 verenluovuttajaa ja 179 raskaana olevaa naista. Lisäksi tutki-
musaineistoon kuului 17 hedelmöityshoidoissa käynyttä naista, joilla hedelmättö-
myyden syy oli jokin muu kuin munanjohdinvaurio. 
Immuunivastetta vaimentavalla interleukiini-10-sytokiinilla (IL-10) ja sitä koo-
daavan IL10-geenin polymorfismilla -1082 A/G oli huomattava vaikutus klamydian 
indusoimaan sytokiinituotantoon. IL-10:n tuotanto heijastui myös tulehdusvastetta 
edistävien sytokiinien interferoni-γ:n (IFN-γ) ja tuumorinekroositekijän (TNF) pitoi-
suuksiin, sekä lymfosyyttien jakautumisvasteeseen. IL10 -1082 AA -genotyyppi 
liittyi matalaan IL-10-tuotantoon, ja se yhdistettiin myös korkeaan vakavan munan-
johdinvaurion riskiin. 
IFN-γ-sytokiinia koodaavan IFNG-geenin polymorfismin +874 A/T ei havaittu 
liittyvän taudinkuvaan. Tämä polymorfismi oli kuitenkin yhteydessä lymfosyyttien 
jakautumisvasteeseen ja IFN-γ-tasoihin. Polymorfismit IFNG +874 A/T ja 
IL10 -1082 A/G vaikuttivat yhdessä klamydian aiheuttaman lymfosyyttien jakautu-
misvasteen voimakkuuteen. Polymorfismit IL-12- ja TNF-sytokiineja koodaavissa 
geeneissä liittyivät myös taudinkuvaan, mutta niiden vaikutusmekanismien selvittä-
minen edellyttää vielä lisätutkimusta.  
Tutkimustulokset osoittavat, että klamydian herättämän puolustusreaktion voi-
makkuus on geneettisesti säädelty, ja geneettinen taipumus voimakkaaseen tuleh-
dusvasteeseen klamydiainfektion aikana lisää alttiutta kudosvaurioiden kehittymisel-
le. 
 
Avainsanat: Chlamydia trachomatis, geenipolymorfismi, interferoni-γ, interleukiini-
10, soluvälitteinen immuunivaste, sytokiinit  
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1 Introduction 
Chlamydia trachomatis is the most common bacterial sexually transmitted disease 
worldwide, being diagnosed in over 90 million people each year (Starnbach & Roan 
2008). In Finland C. trachomatis infection incidence is following the global trend, 
and the prevalence has risen by 60% since the mid-1990s, with over 13 000 cases 
being reported annually (The Statistical Database of the Infectious Diseases Regis-
ter, 2011). The infection is typically asymptomatic but it can still cause long-term 
inflammation (Black 1997). Because of its symptomless nature, C. trachomatis in-
fection is particularly difficult to confine (Stamm 1988, Zimmerman et al. 1990, 
Thejls et al. 1991). Asymptomatically infected persons do not seek testing or treat-
ment and represent a reservoir for future transmission. In addition, repeat C. tra-
chomatis infections are common and protective immunity seems to be short-lived 
(Batteiger et al. 2010). 
The highest prevalence of C. trachomatis infection is seen in young sexually ac-
tive men and women of 20–25 years of age (The Statistical Database of the Infec-
tious Diseases Register, 2011) but complications may be discovered several years 
later when affected woman try to become pregnant. C. trachomatis infection can 
reduce fertility both in men (Joki-Korpela et al. 2009) and women but the damage to 
reproductive organs is seen more clearly in women (Paavonen and Eggert-Kruse, 
1999). Persistent or repeated infection can cause changes in the Fallopian tube mu-
cosa, adhesion development inside the tubes and eventually tubal blockage with 
accumulation of fluid (Paavonen & Eggert-Kruse 1999, Lyons et al. 2006). Tissue 
damage is permanent and impairs normal function of the Fallopian tubes, leading to 
subfertility and an increased risk of ectopic pregnancy (Lyons et al. 2006). 
C. trachomatis lower genital tract infection may apparently become resolved 
without long-term complications and only some infected women develop infertility 
(Ramsey 2006). Tubal damage in infertile women also varies greatly in extent, ana-
tomical location and nature (Akande 2007). The T lymphocyte response is crucial in 
the resolution of acute infection but T cells also probably play an important role in 
the pathogenesis of C. trachomatis-associated infertility (Loomis & Starnbach 
2002). Interindividual variation in disease manifestation and the intensity and nature 
of the immune response is probably affected by the genetic background of the host 
(Morré et al. 2009).  
The T cell response is regulated by a complex network of cytokines (Curfs et al. 
1997). The resolution of genital chlamydial infection has been shown to be depend-
ent on interferon-gamma (IFN-γ)-producing CD4+ T cells (Rottenberg et al. 2002), 
which activate macrophages and the cell-mediated immune response (Boehm et al. 
1997). Interleukin-10 (IL-10) plays an opposing role by downregulating the expres-
sion of IFN-γ as well as major histocompatibility complex (MHC) class II antigens 
 THL — Research 85/2012 15 Immunogenetic risk factors of Chlamydia-induced tubal factor infertility 
 
and co-stimulatory molecules on macrophages (Moore et al. 2001). IL-10 may limit 
pathology in the upper genital tract (Hvid et al. 2007) but excessive or mistimed 
production may also inhibit pathogen clearance and result in chronic infection (Yang 
2003, Couper et al. 2008). On the other hand, lack of IL-10 has been linked with 
inflammation-driven pathogenesis in some infectious diseases (Mege et al. 2006). 
Because T cell- and IFN-γ-mediated inflammatory responses are also considered to 
cause tissue scarring (Loomis & Starnbach 2002), careful regulation of the balance 
between IL-10 and IFN-γ and possibly also other cytokines is probably important as 
regards disease outcome. 
The aim of this study was to improve understanding of disease mechanisms in C. 
trachomatis-induced tubal damage. A candidate gene approach was used to identify 
cytokine genes related to susceptibility to and severity of C. trachomatis-induced 
tubal damage. The study was also extended to the mechanism behind genetic asso-
ciation. We analyzed how related polymorphisms affect C. trachomatis-specific 
immune responses. Better knowledge of disease mechanisms is needed to develop 
new preventive strategies. At present the challenge in controlling Chlamydia associ-
ated pathogenesis is to identify and treat infected individuals before tissue damage 
occurs. This may be difficult because infections are often asymptomatic. The genetic 
markers that are associated with disease could be used as diagnostic tools to deter-
mine an individual’s risk to develop later complications. The understanding of dis-
ease mechanisms is also needed for the development of Chlamydia vaccine which 
would be the most effective approach to control infections.  
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2 Review of the literature 
2.1 Chlamydia trachomatis 
2.1.1 History 
Chlamydia trachomatis infections have been known to afflict mankind throughout 
history. Ancient medical texts from Egypt, China, Rome, Greece and Arabia  all 
make reference to trachoma (Wright et al. 2008). The etiologic agent was described 
at the beginning of the 20th century. Chlamydial cytoplasmic inclusions were first 
found in 1907 in conjuctival scrapings from orangutans that were infected with ocu-
lar scrapings from a patient who suffered from trachoma (Halberstaedter & von 
Prowazek 1907). The first suggestion of C. trachomatis genital tract infection was 
made a hundred years ago in 1911 when Lindner described inclusions in urethral 
epithelia in men with non-gonococcal urethritis (Lindner 1911). At about the same 
time, cytoplasmic inclusions were reported in cervical cells from mothers of infants 
with non-gonococcal inflammation of the eye (Heymann 1910). This discovery was 
confirmed in 1911 by Lindner, who detected similar cytoplasmic inclusions in in-
flamed eyes of newborns as well as in cervical and urethral cells from their parents 
(Lindner 1911). 
Since then, knowledge of C. trachomatis has increased enormously as detection 
and study of intracellular pathogens, including Chlamydia, have passed through a 
period of substantial evolution. C. trachomatis was first isolated from the genital 
tract in 1959 from the mother of an infant with conjunctivitis (Jones et al. 1959). 
The development of in vitro cell culture methods enabled the use of new research 
tools such as electron microscopy. Because of the small size and intracellular nature 
of Chlamydia, the microbes were first considered as parasites and then as viruses 
(Budai 2007). In the mid-1960s, after cell culture, cell wall, and antibiotic suscepti-
bility tests had been applied in chlamydial research, it was proven that Chlamydia 
organisms are obligate intracellular bacterial pathogens of higher cells (Moulder 
1964, Budai 2007). 
C. trachomatis was associated with acute salpingitis and pelvic inflammatory 
disease in women in the 1970s (Mårdh et al. 1977, Paavonen et al. 1979, Treharne et 
al. 1979, Paavonen 1980). The development of the micro-immunofluorescence typ-
ing test (MIF) (Wang & Grayston 1970) and enzyme immunoassay (EIA) (Saikku et 
al. 1983) methods in the 70s and 80s gave the first prevalence and serotype data. 
Development of the PCR technique in the 1980s (Mullis & Faloona 1987) opened a 
new diagnostic and research field as regards chlamydial infections. The first suc-
cessful C. trachomatis nucleic acid amplification by PCR was performed in 1989 
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(Griffais & Thibon 1989) and the first commercial nucleic acid amplification test 
was introduced in 1993 (Jaschek et al. 1993).   
Two other species of the Chlamydia genus, C. pneumoniae and C. psittaci, have 
also been recognized to cause disease in humans. C. pneumoniae is a very common 
respiratory pathogen (Kuo et al. 1995) that was classified as a new species of the 
genus Chlamydia in 1989 (Grayston et al. 1989). It has been associated with coro-
nary artery diseases (Saikku et al. 1988). C. psittaci typically infects avian species. 
In humans it can cause a zoonotic respiratory infection called psittacosis (Beeckman 
& Vanrompay 2009). C. psittaci caused a large outbreak of severe psittacosis with a 
20% mortality rate in Europe and North America in 1929–1930. At that time, the 
pathogenic agent was found microscopically to resemble the “trachoma virus” 
(Bedson et al. 1930, Bedson & Bland 1932).  
2.1.2 Developmental cycle 
Chlamydia is an obligate intracellular bacterium that has a unique two-phase devel-
opmental cycle. The bacterium alternates between an infectious extracellular form, 
the elementary body (EB) and a noninfectious intracellular replicating form, the 
reticulate body (RB) (Moulder 1991). EBs are extracellular, metabolically inert 
forms that are able to attach to and invade susceptible host cells. They are internal-
ized in membrane-bound vacuoles, named inclusions. Inside the cell the EBs de-
velop into metabolically active RBs, which divide by binary fission. After multiple 
divisions, the RBs begin conversion back to EBs. The host cell then lyses, releasing 
a new generation of EBs that infect neighboring cells (AbdelRahman & Belland 
2005). The bacteria stay inside the inclusion throughout the intracellular stage, 
which according to the results of in vitro studies lasts for approximately 48–72 h for 
C. trachomatis. The length can vary depending on the infecting strain, host cell and 
environmental conditions (Beatty et al. 1994b).  
In vitro, the developmental cycle can be stalled into a state of persistence with 
morphologically enlarged, aberrant and nondividing RBs. Inducers of this state in-
clude IFN-γ (Beatty et al. 1993), penicillin (Nicholson & Stephens 2002), iron dep-
rivation (Raulston 1997), nutrient starvation (Coles et al. 1993), concomitant herpes 
simplex virus infection (Deka et al. 2006, Deka et al. 2007) and maturation of the 
host cell into a physiologically different state (reviewed by Wyrick 2010). This per-
sistent condition is reversible, yielding infectious EBs on removal of the inducers. 
However, it is still unknown whether aberrant chlamydial RBs occur in vivo and 
whether they contribute to prolonged inflammation and disease complications 
(Wyrick 2010). 
2.1.3 Genome 
C. trachomatis has a relatively small genome. The following C. trachomatis ge-
nomes have been sequenced: trachoma strain A (Carlson et al. 2005), sexually 
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transmitted strain D (Stephens et al. 1998), Swedish variant strain (Seth-Smith et al. 
2009, Unemo et al. 2010) and lymphogranuloma venereum (LGV) strain L2 
(Thomson et al. 2008) and they all contain approximately 1040 kbps. They vary in 
size only by a maximum of 5000 bps and they also share a high level of genome 
sequence conservation (Thomson & Clarke 2010). C. trachomatis strains normally 
have a plasmid, an extrachromosomal element, which is 7.5 kbps in size and present 
at a rate of around 4–8 copies per bacterium. The plasmid seems to be a virulence 
factor and its presence is linked to the ability of the host bacterium to synthesize 
glycogen (Carlson et al. 2008). Only a few viable isolates of plasmid-free C. tra-
chomatis strains have been isolated (An et al. 1992, Farencena et al. 1997, Mag-
banua et al. 2007). Because the plasmid is present in multiple copies and the se-
quence is conserved, it is used as a target in many commercial nucleic acid amplifi-
cation tests (NAATs) (Thomson & Clarke 2010). 
2.1.4 C. trachomatis infections 
C. trachomatis can be divided into two biological types or biovars on the basis of 
their target cells. The trachoma biovar is restricted to the epithelial cells of the eye 
and genital tract whereas the LGV biovar is invasive and proliferates in monocytes 
within lymphatic tissues (Mabey & Peeling 2002, Manavi 2006). The trachoma 
biovar is classified into 15 distinct serovars based on antigenic variation in ompA 
genes that encode the organism’s major outer protein (MOMP). Serovars A, B, Ba 
and C are causative agents of trachoma, a major cause of blindness in sub-Saharan 
Africa, the Middle East and Asia (Burton & Mabey 2009). Serovars D–K are trans-
mitted sexually and are a cause of urogenital tract infection worldwide (Bébéar & de 
Barbeyrac 2009). There are three main LGV serovars, L1, L2 and L3 (Mabey & 
Peeling 2002). 
 
Genital infections 
Globally, C. trachomatis is a major cause of sexually transmitted bacterial infections 
affecting over 90 million people annually (Starnbach & Roan 2008) and the number 
of reported cases has been rising during the past 10 years in Europe and the USA 
(Bébéar and de Barbeyrac, 2009). In both men and women, silent, asymptomatic 
infection is common (Stamm 1988, Zimmerman et al. 1990). Genital chlamydial 
infections are typically diagnosed in young people between 16 and 24 years of age. 
Risk factors of infection include a high frequency of partner change and number of 
partners (LaMontagne et al. 2004). 
In men, C. trachomatis is the commonest cause of non-gonococcal (non-specific) 
urethritis. The symptoms can include dysuria and a moderate clear or whitish ure-
thral discharge (Peipert 2003). Reactive arthritis has also been associated with geni-
tal C. trachomatis infection (Keat et al. 1978). In women, the infection can cause 
cervicitis, which can be asymptomatic, or it may cause vaginal discharge or postcoi-
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tal bleeding. Urethral infection can also be associated with cervicitis. Infection can 
ascend to the upper genital tract and cause endometritis, salpingitis and pelvic in-
flammatory disease (PID) (Paavonen & Eggert-Kruse 1999). In the long term, C. 
trachomatis reduces fertility both in men (Joki-Korpela et al. 2009) and women 
(Paavonen & Eggert-Kruse 1999). 
C. trachomatis infection has also been linked to adverse pregnancy outcomes, in-
cluding chorioamnionitis, placentitis, premature rupture of membranes, and preterm 
birth. However, the existing evidence is relatively weak and mostly based on case-
control studies (Paavonen 2012). Although C. trachomatis is a common cause of 
endometritis, no association between C. trachomatis infection and abnormal placen-
tation has been demonstrated (Tikkanen et al. 2008).   
C. trachomatis infection may be transmitted from mother to the infant at deliv-
ery. It can cause conjunctivitis, nasopharyngeal infection and chlamydial pneumonia 
in infants, with a transmission rate of 50–75% (Peipert 2003). 
 
Trachoma 
Trachoma is the leading infectious cause of blindness worldwide (Resnikoff et al. 
2008) and it is estimated that approximately 1.3 million people are blind and a fur-
ther 1.8 million have low vision because of this disease (Burton & Mabey 2009). 
Trachoma is transmitted by flies, fingers or shared clothes or towels. The disease 
affects the poor living in rural areas where people have limited access to water and 
personal hygiene is difficult (WHO 2006). 
Repeated or prolonged infections produce scarring of the inner part of the upper 
eyelid, which turns the eyelashes inwards so that they scratch the eyeball. This con-
dition is called trichiasis. Poor tear secretion due to scarring leads to drying of the 
eye. These things may lead to scarring of the cornea, which impairs vision (WHO 
2006). Visual loss from trachoma often starts in adulthood and is more common in 
women than men. Trichiasis is a disabling disease causing visual impairment, pain 
and photophobia.  Trachoma is therefore a significant health problem in affected 
communities, with a high disability burden (Burton & Mabey 2009).  
 
Lymphogranuloma venereum 
The LGV serovars may cause disseminated infection. They predominantly infect 
monocytes and macrophages and pass through the epithelial surface to regional 
lymph nodes. In contrast, the A–K serovars are largely confined to mucosal epithe-
lial surfaces of the genital tract and eye (Mabey & Peeling 2002).  
LGV infections are rare in industrialized countries, although the number of re-
ported cases has increased in recent years. Until 2003, LGV was seen only sporadi-
cally in Europe and the small regional outbreaks usually involved migrants or tour-
ists from tropical regions. LGV is endemic in East and West Africa, India, Southeast 
Asia and the Caribbean (Stary & Stary 2008). In 2003 there was an outbreak of LGV 
in Rotterdam, followed by additional reports from other European countries and 
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North America. Most patients have been HIV-positive men (Stary & Stary 2008, 
White 2009). 
2.1.5 Natural history of genital C. trachomatis infection 
Interindividual differences in the clinical course of C. trachomatis infection occur, 
including transmission of the pathogen (Lin et al. 1998, van Valkengoed et al. 
2002), duration of untreated infection (McCormack et al. 1979, Morré et al. 2002, 
Molano et al. 2005) and development of tissue damage (Akande 2007) and late 
complications (Weström et al. 1992). However, knowledge of the natural history of 
untreated genital chlamydial infection in humans is limited and more information on 
factors affecting infection outcome, including spontaneous resolution, persistence 
and development of complications are needed to optimize C. trachomatis prevention 
strategies and to estimate the cost-effectiveness of screening (Geisler 2010). 
Studies indicate that the transmission rate of C. trachomatis infection is relatively 
high. When the infection prevalence was studied in partners of C. trachomatis-
positive patients the transmission rate from patient to partner was between 48% and 
65%. A lower rate was found among asymptomatic populations (screening popula-
tion) (van Valkengoed et al. 2002) and a higher one among subjects attending an 
STD clinic because of symptoms (Lin et al. 1998). 
Three studies have concerned evaluation of the duration of untreated, uncompli-
cated chlamydial infection in humans with follow-up at intervals of at least one year 
(Geisler 2010). In these studies approximately half of the participants cleared the 
infection spontaneously within one year after initial testing (McCormack et al. 1979, 
Morré et al. 2002, Molano et al. 2005). The follow-up time was longest in the study 
by Molano et al., where C. trachomatis clearance was evaluated retrospectively 
using stored cervical specimens from 1995 Colombian women who were enrolled in 
a human papillomavirus (HPV) natural history study. The study was conducted 
among 82 women who tested positive at baseline. The infection had cleared in 54% 
by 1 year of follow-up, 82% by two years and 94% by four years (Molano et al. 
2005). The accuracy of estimates of C. trachomatis infection duration is limited 
because the studies lack exact timing of initial infection, and bias due to the fact that 
repeated infections cannot be considered. Animal models of persistent infections 
differ fundamentally from human infection, limiting their use as regards mimicking 
human natural infection. In mice the infection is cleared within 3–4 weeks (Miyairi 
et al. 2010). Compared with mice, in pigtailed macaques the infection is more per-
sistent (Wolner-Hanssen et al. 1991).  
Chlamydial IgG antibodies can persist at stable levels for years after infection 
(Puolakkainen et al. 1986). Many studies have shown that serological markers of 
past C. trachomatis infection are associated with infertility (Robertson et al. 1987, 
Toye et al. 1993) and an increased risk of ectopic pregnancy (Chow et al. 1990, 
Brunham et al. 1992). However, only some women develop tubal damage as a con-
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sequence of infection, while most women clear the infection without long-term 
complications. Studies among symptomatic patients visiting STD clinics or emer-
gency departments have shown that 2–4.5% of women with untreated C. trachoma-
tis infection develop PID within a two-week interval between testing and returning 
for treatment (Bachmann et al. 1999, Geisler et al. 2008). Symptomatic PID in-
creases the risk of infertility (Weström et al. 1992, Ness et al. 2002). In a study by 
Weström et al. a patient group of 1844 women with laparoscopically verified, symp-
tomatic PID were followed up for several years in regard to adverse outcomes. In 
this study population there were various reasons for PID and not all were Chlamydia 
related. The study showed that severe inflammation predicted later fertility prob-
lems. In addition, each repeated episode of PID roughly doubled the rate of TFI. 
After 1, 2, and 3 or more episodes the rates were 8.0%, 19.5% and 40.0% (Weström 
et al. 1992). Epidemiologic studies have shown that the cumulative risk of PID 
(Kimani et al. 1996, Hillis et al. 1997) and long-term reproductive consequences 
(Hillis et al. 1997, Bakken et al. 2007) increase according to the number of repeat C. 
trachomatis infections. However, it remains unclear whether the increased risk is 
due to longer exposure time (additive risk connected with each infection) or does the 
repeated infection induce more immunopathology (more than the additive risk con-
nected with each infection). 
Antibodies to chlamydial heat shock protein 60 kDa (HSP60) (Paavonen et al. 
2003) and C. trachomatis EBs (Koskela et al. 2000, Anttila et al. 2001) as well as 
diagnosed C. trachomatis infection (Lehtinen et al. 2011) have been associated with 
cervical carcinoma. Although human papillomavirus (HPV) is necessary as regards 
the development of cervical carcinoma (Bosch et al. 1995, Walboomers et al. 1999, 
Wallin et al. 1999) C. trachomatis lower genital tract infection may act as a cofactor 
in carcinogenesis. Chlamydia induces inflammation and metaplasia and metaplastic 
cells are potential target cells for HPV. Also, C. trachomatis modulates host immune 
response and inhibits apoptosis (Paavonen 2012). 
2.1.6 Diagnostics and treatment 
Nucleic acid amplification tests have become the dominant tests for diagnosing 
genital infections with C. trachomatis during the last five years. Such tests became 
commercially available less than 20 years ago and their evolution has continued ever 
since, as has the understanding of their use (Schachter 2010). A number of the tests 
utilize the cryptic plasmid that exists in about 4–8 copies per EB. Currently the most 
sensitive C. trachomatis test, GenProbe Aptima Combo2, targets the rRNA se-
quence that exists in several hundred copies per EB and thus has an inherent advan-
tage over assays that target DNA (Ikeda-Dantsuji et al. 2005). 
Specimen collection has also become easier as the tests have evolved in efficacy. 
Before the era of NAATs the specimen types required for culture were endocervical 
swabs from women and urethral swabs from men. With NAATs, clinical examina-
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tion is not required and self-collected first-catch urine specimens perform well in 
NAATs both in men and women (Schachter 2010). In women, self-collected vaginal 
swab specimens are also used and they have been shown to be better than urine 
samples (Chernesky et al. 2005, Schachter et al. 2005).  
Single-dose therapy with azithromycin (1 g) is an efficient treatment for uncom-
plicated lower genital tract C. trachomatis infection. A 7-day course of doxycycline 
also gives comparable results. Both patients and their partners should be treated 
(Workowski & Berman 2010). 
 
Lessons learned from a new variant of C. trachomatis 
A reminder of the importance of diagnostic test design arose in Sweden in 2006 
when a sudden fall in numbers of laboratory-confirmed C. trachomatis infections in 
some Swedish counties led to recognition of a highly prevalent new variant of C. 
trachomatis (Söderblom et al. 2006). Because of a 377-bp deletion in a cryptic 
plasmid at the target sequence for amplification, the variant had escaped detection 
by two widely used commercial NAATs, those manufactured by Abbott Laborato-
ries and by Roche Diagnostics. The new variant belongs to serovar E and does not 
have any obvious biological differences compared with the wild-type strain (Unemo 
et al. 2010).  
The rapid transmission of the new variant in Sweden was due to a strong diag-
nostic selective advantage – the variant became clearly more prevalent in counties 
where the Roche and Abbott tests were used (Herrmann et al. 2008). The emergence 
and spread of the new variant highlighted the fact that selection of the target gene 
for amplification is important. Although the plasmid region is highly conserved, its 
biological function and necessity to pathogen is not well known and it is therefore a 
risky target for diagnostics. Multitarget assays detecting essential conserved non-
cryptic multicopy species-specific DNA or RNA sequences should be used for de-
tection (Unemo & Clarke 2011). 
 
Serology 
C. trachomatis serology is no longer used as diagnostic tool for acute infections, but 
it is still used in the fertility work-up as a screening test to estimate the risk for tubal 
pathology (Akande et al. 2003). Nowadays serology has a new role in population-
based epidemiological studies and has proven useful in evaluating on-going trends 
of infection prevalence and incidence rates at a population level (Johnson & Horner 
2008, Lyytikäinen et al. 2008a, Lyytikäinen et al. 2008b). Serology is also used to 
evaluate the impact of C. trachomatis screening programs at a population level. 
Various serological tests have been developed for the detection of C. trachomatis-
specific antibodies, including a complement fixation test, MIF, EIA and im-
munoblotting (Paavonen 2012). 
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2.2 Immune response to C. trachomatis infection 
Because of difficulties in specifying the time of exposure to infection and following 
the development of a local immune response at the site of infection in humans, re-
searchers have used several animal models of chlamydial infection to examine the 
immune response that occurs in the female genital tract after infection (Darville & 
Hiltke 2010). Mouse models show that the response to primary chlamydial infection 
occurs within a few days after inoculation of infection and is characterized by mu-
cosal and submucosal infiltration of polymorphonuclear neutrophils and monocytes, 
and T cells accumulate at the site later (Morrison 2000, Morrison & Caldwell 2002). 
Unlike other mucosal surfaces, genital mucosa lacks underlying organized lym-
phoid elements (Neutra et al. 1996, Kelly 2006). In a mouse model, antigen-specific 
naive T cells are activated and differentiate into effector T cells in the iliac lymph 
nodes that drain antigen from the genital tract (Cain & Rank 1995, Roan et al. 2006). 
Thereafter, the T cells migrate to the genital tract and accumulate at the site of infec-
tion (Kelly & Rank 1997), where they play a critical role in controlling it (Rank & 
Barron 1983, Ramsey & Rank 1991, Morrison et al. 1995). 
2.2.1 Innate immunity 
The mucosal barrier of the genital tract provides the first line of host defense against 
invading microbes (Quayle, 2002). Proliferation and maturation of vaginal epithelial 
cells is under hormonal regulation (Darville 2006) and in a mouse model the ability 
of C. trachomatis to go through this physical barrier is influenced by the stage of the 
estrus cycle (Roan & Starnbach 2008). At peak estrogen levels, the vaginal epithe-
lium reaches its maximum thickness (Quayle 2002). 
C. trachomatis primarily infects epithelial cells, which recognize microbial in-
variant structures via pathogen recognition receptors (PRRs) (Joyee & Yang 2008). 
The infected epithelial cells initiate immunity effector mechanisms by inducing the 
production of proinflammatory cytokines that also have chemoattractant functions, 
such as IL-1α, IL-6, IL-8, TNF, GROα and GM-CSF (Rasmussen et al. 1997). 
Chemokines recruit neutrophils and monocytes to the site of infection (Molestina et 
al. 1999, Dessus-Babus et al. 2000). Neutrophils play an important role in the first 
stage of infection. They are the only myeloid cells whose lysosomes readily fuse 
with phagosomes containing EBs (Darville 2006). They are capable of killing EBs 
and both oxygen-dependent and oxygen-independent mechanisms are active in the 
process (Yong et al. 1982, Söderlund et al. 1984, Zvillich & Sarov 1985, Yong et al. 
1986). In addition, NK cells are important at the early stage of infection as they are 
able to produce IFN-γ, which is an essential cytokine in defense against C. tra-
chomatis infection (Tseng & Rank 1998).  
Macrophages and monocytes play central roles in both innate and adaptive im-
munity. Macrophages are present as Langerhans-like cells in the vagina and cervix 
(Booker et al. 1994, Darville 2006). Compared with neutrophils, macrophages per-
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sist much longer at the site of inflammation. They are longer-lived than neutrophils, 
and can undergo cell division at the inflammatory site (reviewed by Darville 2006). 
Macrophages aid in eradication of Chlamydia in infected cells but Chlamydia can 
potentially survive and replicate within infected macrophages (Airenne et al. 1999). 
The ability of Chlamydia to inhibit phagosome-lysosome fusion varies between 
chlamydial species and serovars (La Verda & Byrne 1994). Macrophages activate 
and regulate the development of adaptive immunity by producing the cytokines IL-
12 and IL-10 (O'Garra & Murphy 2009). They also process and present antigens to 
T cells (Trombetta & Mellman 2005) and therefore provide a link between innate 
and adaptive immunity. 
2.2.2 Adaptive immunity 
An adaptive immune response is necessary to limit C. trachomatis infection and 
generate antigen-specific immunity. Both T cells and B cells are activated during 
chlamydial infection (Morrison & Morrison 2000) but T cells have a more important 
role in host defense. The necessity of T cells in control of C. trachomatis infection 
was documented in the mid-1980s, when it was observed that nude mice, which lack 
T cells, suffer from chronic infection, whereas wild-type mice are able to clear the 
infection within 20 days (Rank et al. 1985). The role of B cells is to produce anti-
bodies and mediate immunity to C. trachomatis by neutralizing infectivity and en-
hancing phagocytosis of EBs (Peeling et al. 1984, Peterson et al. 1991). However, 
antibodies are unable to access the Chlamydia organisms established in intracellular 
infection and in mouse models antibodies have not been found to be essential in 
controlling primary C. trachomatis infection (Su et al. 1997). 
Both CD4+ and CD8+ T cells contribute to defense (Loomis & Starnbach 2002), 
but CD4+ T cells appear to be more important during natural infection (Magee et al. 
1995, Morrison et al. 1995, Williams et al. 1997). CD4+ and CD8+ T cells recog-
nize antigens that are processed through different pathways. CD4+ cells recognize 
antigens that are engulfed by antigen-presenting cells (APCs). Antigens are proc-
essed by proteases within the lysosomal compartments of APCs, and the resulting 
peptides are presented by MHC class II molecules to CD4+ T cells (Trombetta & 
Mellman 2005). APCs can process Chlamydia EBs phagocytosed from extracellular 
spaces within tissues and they also present RB antigens by engulfing infected cells 
that harbor RB organisms. Therefore, CD4+ T cells may recognize antigens from 
multiple stages of C. trachomatis infection (Roan & Starnbach 2008).  
Infected epithelial cells present chlamydial antigens in complexes with MHC 
class I to CD8+ T cells. A number of chlamydial proteins are secreted during the 
intracellular stage of the developmental cycle from inclusion into the host cell cyto-
plasm (Zhong et al. 2001, Clifton et al. 2004) and these proteins serve as CD8+ T 
cell antigens (Fling et al. 2001, Starnbach et al. 2003). The cytosolic antigens are 
processed by the proteasome into peptide fragments (Cresswell et al. 2005).  
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Because reinfection is common (Niccolai et al. 2007), it seems that individuals 
infected with Chlamydia do not develop long-term protective immunity (Batteiger et 
al. 2010). Some degree of immunity develops, but it is not necessarily able to pre-
vent infection (Katz et al. 1987). According to epidemiological data, previous C. 
trachomatis infection does not seem to protect against reinfection, but, in contrast, 
some studies have shown that a documented history of chlamydial infection is asso-
ciated with an increased risk of current infection (Hiltunen-Back et al. 2001, Riet-
meijer et al. 2002). In studies carried out in the US, the median time to reoccurrence 
of C. trachomatis infection has typically been found to be 5–7 months, with the risk 
being higher among young women than among older women (Burstein et al. 1998, 
Burstein et al. 2001). However, repeat infections are associated with number of 
partners (Hiltunen-Back et al. 2001), suggesting that risk-taking sexual behavior is 
associated with C. trachomatis infection. Therefore, these observations do not ex-
clude the concept of protective immunity, but suggest that it is partial at best. The 
short term protective immunity is probably due to the inability of CD4+ cells to be 
retained in the genital tract. CD4+ cells are required for immunity, but when the 
chlamydial organisms and antigens are eliminated from the genital tract, homing 
receptors for CD4+ cells are downregulated and T cells cannot remain or home to 
the site (Kelly & Rank 1997, Rank 2006).  
2.2.3 Cytokine profile and T helper subpopulations 
The cytokine environment during the early stages of infection has a significant role 
in development of the T cell-mediated immune response, and it is also demonstrated 
to affect the outcome in many diseases (Belardelli 1995). Classification of CD4+ T 
cells into Th1 and Th2 cells (also known as Type 1 and Type 2 T helper cells) is 
based on the different functions and cytokine profiles of the cell types (Mosmann et 
al. 1986). Th1 cells activate macrophages and phagocytic functions via production 
of IFN-γ and the promote secretion of IgG2a opsonizing antibodies by the B cells. In 
contrast, Th2 cells mediate phagocyte-independent responses. Th2 cells produce IL-
4, which activates B cell-mediated antibody responses at a broad level, and it also 
inhibits macrophage function (Romagnani 1996). Th1 and Th2 subsets cross-
regulate each other’s functions. The cytokines released from Th1 and Th2 cells 
stimulate their own subsets and, at the same time, they inhibit cytokine production 
and function of the other subset (Belardelli 1995).  
Extensive evidence supports the concept that the Th1 and Th2 subsets and their 
main cytokines, IFN-γ and IL-4, mediate opposite effects on a variety of immune 
parameters, including several functional activities of macrophages and the develop-
ment of T cell cytokine profiles (Kelso 1995). After introduction of the Th1/Th2 
paradigm in the 1980s (Mosmann et al. 1986), the theory became widely accepted in 
the field of immunology. However, many murine and human T cell clones do not fit 
the Th1/Th2 classification and the model was soon recognized to be oversimplified 
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(Kelso 1995). In addition, experimental evidence from studies on autoimmune dis-
eases has contradicted the Th1/Th2 paradigm, suggesting that some piece of the 
puzzle is missing. Although Th1 cells were thought to play a major role in tissue 
damage, the administration IFN-γ did not worsen autoimmune disease, and neither 
did blocking of IFN-γ ameliorate it – just the opposite (Basso et al. 2009). The dis-
covery of a third member of the T helper set, IL-17-producing Th17 cells 
(Harrington et al. 2005) started to explain the mechanisms of autoimmune disease 
and immunopathology (Bettelli et al. 2007). Th17 cells are a distinct lineage that 
does not share developmental pathways with either Th1 or Th2 cells (Harrington et 
al. 2005, Park et al. 2005). The Th17 subset is highly proinflammatory and has been 
associated with autoimmune disorders (Bettelli et al. 2007). The Th17 response has 
also been implicated in the development of immunopathology in other models of 
infection (Torrado & Cooper 2010, Yang et al. 2011). 
At present, CD4+ T helper cells are divided into four main subsets: Th1, Th2, 
Th17 and regulatory T (Treg) cells (Kaufmann 2007), presented in Figure 1. In addi-
tion, Th9, Th22 (Annunziato & Romagnani 2009) and follicular helper T (TFH) cell 
(Crotty 2011) subpopulations have been introduced, suggesting that CD4+ cells do 
not fit into a simple classification. Of Treg cells, two main groups have been identi-
fied: naturally occurring CD4+CD25+ Tregs, which may develop in the thymus and 
regulate self-reactive T cells in the periphery, and inducible Tregs, which develop in 
the periphery from conventional CD4+ T cells after exposure to signals such as 
regulatory cytokines (O'Garra & Vieira 2004). Treg cells can limit Th1 and Th2 cell 
responses indirectly by modulating APC function or directly by way of cell–cell 
contact (Belkaid 2007).  
In murine models of C. trachomatis infection, a Th1 type of immune response 
has been shown to mediate resolution of infection and a Th2 type of immune re-
sponse is associated with an inadequate cell-mediated response and persistence of C. 
trachomatis infection (Perry et al. 1997, Yang 2003). However, in human C. tra-
chomatis sexually transmitted infection a Th2 type of response has not been reported 
(Stephens 2003), suggesting that activation of the Th2 subset is not likely to be the 
reason for the pathological picture. Tregs and Th17 cells are probably also involved 
in pathogenesis but their roles have not yet been studied widely. 
The cytokine profile also influences host defense in C. trachomatis infection. In 
particular, the balance between IFN-γ and IL-10 is a potential determinant of infec-
tion outcome, because these two cytokines play opposing roles in regulating the 
immune response. IFN-γ activates macrophages to control intracellular infections 
(Boehm et al. 1997), while IL-10 has a strong immunosuppressive effect on cell-
mediated immunity (CMI) (Couper et al. 2008), which can inhibit pathogen clear-
ance (Mege et al. 2006). On the other hand, IL-10 has also been shown to prevent 
inflammation-driven tissue pathology (Couper et al. 2008). Production of IFN-γ 
from NK cells and T cells is induced by IL-12, which is secreted in the early phase 
of infection (Trinchieri 2003) and might therefore be an important modulator of a 
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favorable cytokine environment. TNF is also an interesting cytokine because of its 
multifunctional effects on host immune responses (Locksley et al. 2001) and its 
possible involvement in fibrosis and tissue remodeling in disease pathogenesis 
(Banno et al. 2004). 
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Figure 1. Four main populations of CD4+ T cells. Regulatory T cells (Treg cells) 
control and prevent excessive immune responses. T helper 1 (Th1) cells 
activate macrophages and promote cell-mediated immunity by producing 
interferon gamma (IFN-γ) and interleukin 2 (IL-2) cytokines. T helper 2 
(Th2) cells promote humoral immunity and defense against helminths by 
producing IL-4 and IL-5 cytokines. Th17 cells produce IL-17. (Modified after 
Kaufmann 2007) DC, dendritic cell; GM-CSF, granulocyte-macrophage 
colony-stimulating factor; TGF, transforming growth factor. 
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2.2.3.1 IFN-γ 
The functions of IFN-γ are important in CMI against intracellular microbes. IFN-γ is 
produced by CD4+ and CD8+ T cells and NK cells and it activates macrophages to 
kill phagocytosed microbes (Boehm et al. 1997). IFN-γ is necessary for protection 
against C. trachomatis infection (Rottenberg et al. 2002, Gondek et al. 2009) and 
deficiency in its production in vitro has been shown to promote persistent chlamy-
dial infection (Beatty et al. 1993). 
IFN-γ has been shown to limit C. trachomatis infection directly through a variety 
of mechanisms (Loomis & Starnbach 2002). It induces the expression of in-
doleamine 2,3-dioxygenase (IDO), which degrades intracellular tryptophan, limiting 
Chlamydia replication (Taylor & Feng 1991). IFN-γ also increases host nitric oxide 
(NO) production, which restricts Chlamydia growth in vitro (Ramsey et al. 2001) 
and downregulates transferrin receptors (Byrd & Horwitz 1993), resulting in intra-
cellular iron deficiency, which may also limit chlamydial growth (Igietseme et al. 
1998). It also indirectly controls intracellular infections by augmenting host immune 
responses. IFN-γ upregulates macrophage phagocytic potential and the expression of 
MHC I and MHC II antigens, leading to enhanced presentation of microbial antigens 
to both CD4+ and CD8+ T cells (Boehm et al. 1997), which enhances the CMI re-
sponse. 
The inhibitory effect of IFN-γ on chlamydial growth differs markedly among C. 
trachomatis strains. Strains associated with sexually transmitted infections (STIs) 
are less sensitive to the direct action of IFN-γ than ocular serotypes in epithelial cell 
cultures (Morrison 2000). This is probably because the STI serotypes are able to 
synthesize tryptophan of indole, while the ocular serotypes are not (McClarty et al. 
2007). There is also variation in sensitivity to IFN-γ between different C. trachoma-
tis STI strains, which can influence the virulence of the bacteria and clinical out-
come of the infection (Morrison 2000). 
An unsuccessful immune response that leads to persistent infection may be due 
to an insufficient amount of IFN-γ. The level of IFN-γ is affected by the expression 
of other cytokines that regulate its production, such as IL-10, IL-4 or IL-12, and 
probably also by genetic predisposition to IFN-γ expression. The IFN-γ gene IFNG 
is located in chromosome 12 and contains 4 exons that span 5.4 kb. Intronic poly-
morphisms, +874 A/T and a CA repeat microsatellite, have been associated with 
IFN-γ production levels (Pravica et al. 2000). The promoter SNP -179 T/G has also 
been associated with IFN-γ production levels (Bream et al. 2002, Gonsky et al. 
2006). In the field of C. trachomatis research, certain IFNG polymorphisms have 
been associated with scarring trachoma (Natividad et al. 2005). 
2.2.3.2 IL-12 
IL-12 is an important mediator of the early innate immune response to intracellular 
microbes. IL-12 induces the production of IFN-γ and promotes the differentiation of 
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Th1 cells (Trinchieri 2003). It is mainly produced by monocytes, macrophages and 
dendritic cells, which are the first leukocytes to interact with pathogens (O'Garra & 
Murphy 2009). IL-12 is a heterodimeric cytokine, encoded by two separate genes, 
i.e. IL12A, which encodes subunit p35 and IL12B, which encodes subunit p40. The 
bioactive form of IL-12 is a 75-kDa heterodimer (IL-12p70) comprised of disulfide-
linked p40 and p35 subunits (Gately et al. 1998). 
Subunit p40 is a common building block of IL-12 and IL-23 cytokines 
(Trinchieri 2003). IL-12 and IL-23 cytokines are closely related and they are both 
involved in the regulation of T cell responses, yet they have distinct roles. IL-12 is 
important in induction of IFN-γ production and activation of Th1-type immunity, 
whereas IL-23 has been shown to play a key role in induction of the newly described 
Th17 cells that currently are considered to be responsible for the inflammation-
driven pathogenesis, rather than the Th1 subset (Goriely et al. 2009). 
The host genetic background can potentially affect the production level of IL-12. 
Because IL-12 induces IFN-γ production, its expression may also be reflected in 
IFN-γ secretion. Several SNPs of both the IL12A and IL12B genes have been identi-
fied and some of them have been associated with infectious diseases. In particular, 
the SNP marker 1188 (rs3212227) on the 3’-flanking region of IL12B (Figure 2) has 
been linked to susceptibility to psoriasis (Cargill et al. 2007, Nair et al. 2008) and 
also to recurrent chlamydial infections (Geisler et al. 2010). 
 
 
 
Figure 2. The figure shows the SNP locations in IL12A and IL12B genes. 
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2.2.3.3 IL-10 
IL-10 was first described as a cytokine synthesis-inhibitory factor (Fiorentino et al. 
1989) and it was soon recognized to have a wide range of immunosuppressive func-
tions (Moore et al. 1993). IL-10 is a key immunosuppressive cytokine during infec-
tion with viruses, bacteria, fungi, protozoa and helminths. It inhibits the activity of 
Th1 cells, NK cells and macrophages by downregulating the expression of proin-
flammatory cytokines such as IFN-γ, IL-12 and TNF. It also inhibits the expression 
of MHC class II antigens and co-stimulatory molecules on macrophages (Couper et 
al. 2008). IL-10 can be produced by many different types of cells such as macro-
phages, dendritic cells, B cells and also various subsets of CD4+ and CD8+ T cells 
(Moore et al. 2001).  
Because of its immunosuppressive effect on CMI, IL-10 has a double-edged na-
ture in infectious diseases. On one hand, excessive or mistimed IL-10 production is 
connected with impaired immune responses and persistence of bacteria and viruses. 
On the other hand IL-10 has an important role in the prevention of immunopathol-
ogy that may result from excessive inflammatory responses (Mege et al. 2006). In 
humans, IL-10 has been reported to be involved in the persistence of infections 
caused by bacteria such as Coxiella burnetii (Capo et al. 1996, Honstettre et al. 
2003), M. tuberculosis (Tufariello et al. 2003) and Bartonella spp. (Capo et al. 2003, 
Mege et al. 2006). IL-10 has been shown to prevent the tissue pathology associated 
with excessive Th1 and CD8+ T cell responses in studies on infections involving 
Toxoplasma gondii (Wilson et al. 2005), Trypanosoma spp. (Hunter et al. 1997, 
Magez et al. 2002), Plasmodium spp. (Rudin et al. 1997), Mycobacterium spp. 
(Bekker et al. 1998) and herpes simplex virus (HSV) (Suvas et al. 2004). In addition, 
IL-10 has been reported to diminish the destructive effect of C. trachomatis induced 
by IL-1 on the epithelium in a human Fallopian tube culture model (Hvid et al. 
2007). 
Genetic predisposition to infection-induced IL-10 production may affect the 
clinical outcome of C. trachomatis infection. Interindividual variance is seen in the 
levels of IL-10 secretion from stimulated peripheral blood mononuclear cells 
(PBMCs) and the variability has been found to have a hereditary component 
(Westendorp et al. 1997). Several common polymorphisms have been identified in 
the promoter region of the gene, including IL10 -1082 A/G, -819 C/T and -592 C/A 
SNPs. These SNPs are in linkage disequilibrium and form three haplotypes: GCC, 
ACC and ATA, where GCC is usually associated with high IL-10 production and 
ACC and ATA with low production (Turner et al. 1997). The functionality of the 
IL10 -1082/-819/-592 haplotypes has been studied by using luciferase reporter as-
says and the ATA construct was found to have weaker transcriptional activity than 
the GCC construct (Crawley et al. 1999). 
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2.2.3.4 TNF 
Tumor necrosis factor is a multifunctional cytokine that mediates inflammation, the 
immune response and apoptosis (Locksley et al. 2001). Lipopolysaccharide (LPS) is 
strong stimulus for TNF production and large amounts of this cytokine may be pro-
duced in infections by gram-negative bacteria. It is mainly produced by monocytes 
and macrophages but activated T cells, NK cells and mast cells can also produce 
TNF (Vassalli 1992). 
TNF stimulates the recruitment of neutrophils and monocytes to sites of infection 
and activates these cells to eradicate microbes (Vassalli 1992). It has antichlamydial 
effects both in vitro (Shemer-Avni et al. 1988) and in vivo in a murine model 
(Williams et al. 1990). Besides its effects on host immune responses, TNF is also 
involved in fibrosis and tissue remodeling (Piguet et al. 1989, Banno et al. 2004), 
making it an interesting target in Chlamydia pathogenesis research. In trachoma 
studies increased levels of TNF transcripts in tear fluid have been associated with 
scarring trachoma (Conway et al. 1997). 
TNF -308 A/G is the most commonly studied TNF polymorphism. The SNP is 
located in the promoter region of the gene and has been associated with many dis-
eases. However, the literature covering the role of the TNF -308 A/G polymorphism 
in TNF production is inconsistent (Bayley et al. 2004) and the stimulus and studied 
cell type can affect TNF expression and its association with the -308 SNP (Kroeger 
et al. 2000). It is also possible that the association with disease manifestation is de-
rived from a gene nearby that is linked to TNF, because the gene lies in an MHC III 
area which exhibits extensive linkage disequilibrium. Trachoma studies indicate that 
the TNF -308 A marker is part of a more complex picture. The TNF locus and also 
related neighboring genes such as that for lymphotoxin alpha affect the risk of se-
vere outcome in ocular C. trachomatis infection (Natividad et al. 2007). 
2.3 Pathogenesis of C. trachomatis infection 
The hallmark of an adverse outcome of genital and ocular C. trachomatis infection 
is fibrosis (Ramsey 2006), which is the ultimate reason for the fertility problems in 
genital infections and impaired sight in trachoma disease. In the Fallopian tube, C. 
trachomatis has a direct cytotoxic effect on the mucosa, resulting in loss of mi-
crovilli (Cooper et al. 1990). In acute infection the inflammation and edema associ-
ated with chlamydial salpingitis also reduce ciliary activity. However, the irreversi-
ble and permanent tubal damage is consequence of a host immune response to per-
sistent or repeated infections (Lyons et al. 2006). 
The pathologic consequences of infections are well established but the mecha-
nisms that result in tissue damage are not fully understood. Persistent and repeated 
infections are key concepts in chlamydial pathogenesis. In women, C. trachomatis 
genital infection can persist for years (Molano et al. 2005) and during long-term 
inflammation tissue remodeling and scarring have time to progress. 
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2.3.1 Role of epithelial cells and the adaptive immune response 
At present it seems clear that chlamydial pathogenesis is a consequence of the host 
immune response to infection. Along with adaptive responses, innate immunity 
mechanisms and infected epithelial cells are important factors in host response and 
pathogenesis (Debattista et al. 2003).  
Infected epithelial cells initiate defense mechanisms by secreting chemokines 
that recruit inflammatory leukocytes to the site of infection (Rasmussen et al. 1997), 
plus dedicated innate immune cells such as monocytes, macrophages and neutro-
phils, and adaptive immune cells such as lymphocytes contribute to inflammation 
and pathogenesis (reviewed by Darville & Hiltke 2010). Infected host epithelial cells 
also serve as reservoir of infection (Stephens 2003). Infected epithelial cells release 
the cytokine IL-1, which stimulates additional cytokine secretion and augments the 
inflammatory response. A study by Hvid et al. demonstrated that in a Fallopian tube 
organ culture model IL-1 is the initiator of Fallopian tube destruction. The pathology 
could be prevented by using IL-1 receptor antagonist (IL-1RA), indicating a direct 
role of this cytokine in pathogenesis. In addition, immunosuppressive IL-10 was 
found to diminish the effect of IL-1 (Hvid et al. 2007). 
Because the pathogenesis occurs during repeated or persistent infection (Hillis et 
al. 1997), Chlamydia-specific adaptive T cell responses are considered to be impor-
tant players in the development of tissue damage (Brunham & Peeling 1994, Loomis 
& Starnbach 2002). It is paradoxical that the primary protective action mediated by 
T cells and CMI is also associated with pathology. A failed or weak Th1 cell re-
sponse can result in persistent infection and pathology (Beatty et al. 1994a, Mittal et 
al. 1996), but an exaggerated or over-stimulated Th1 response can also mediate in-
flammation-driven pathogenesis (Morrison et al. 1989, Beatty et al. 1994a, Ault et 
al. 1996). Therefore, the immune response needs to be balanced and carefully regu-
lated (Debattista et al. 2003). Treg and Th17 cells might also have a role in the dis-
ease process, but as yet it is unclear. 
2.3.2 Response to heat shock proteins 
Chlamydial HSP60 is a major immune target of both humoral and cell-mediated 
immune mechanisms (Persson et al. 1999, Kinnunen et al. 2002a) and might play a 
role in pathogenesis. Heat shock proteins (HSPs) are conserved proteins present in 
all prokaryotic and eukaryotic organisms and they are divided into four structurally 
related groups based on their molecular weights. HSPs function as chaperones in 
folding, assembly and translocation of newly synthesized or damaged proteins. They 
have important roles in cell survival and recovery from metabolic disturbances, re-
flected in increased HSP synthesis during diverse forms of stress, such as infection, 
inflammation and exposure to harmful chemical or environmental factors (Kinnunen 
et al. 2001, Borges & Ramos 2005). Stressful growth conditions such as nutrient 
depletion, the presence of penicillin or low levels of IFN-γ can induce incomplete 
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Chlamydia growth and organism persistence in vitro (Beatty et al. 1994a). In persis-
tent stage, Chlamydia is in a nonreplicative and noninfectious but metabolically 
active form, which explains why the production of chlamydial HSP60 in comparison 
with other chlamydial proteins increases during persistent infection (Beatty et al. 
1993, Gérard et al. 1998, LaVerda et al. 1999). 
Elevated levels of chlamydial HSP60-specific antibodies have been found in in-
dividuals with severe disease outcomes. In both genital tract disease (Toye et al. 
1993, Peeling et al. 1997) and trachoma (Peeling et al. 1998, Hessel et al. 2001), 
chlamydial HSP60 has been associated with pathology. Chlamydial HSP60 and 
human mitochondrial HSP60 share 50% sequence identity and cross-reactive anti-
body-binding epitopes from chlamydial HSP60 and human HSP60 have been identi-
fied (Yi et al. 1993). The cross-reactive epitopes, recognition of self-HSP and im-
mune tolerance breakdown via an autoimmune mechanism have been hypothesized 
as disease mechanisms. However, the evidence does not support the hypothesis of an 
autoimmune mechanism (Stephens 2003). In addition, in C. pneumoniae infection 
and coronary artery disease it has been reported that serological reactivity to chla-
mydial HSP60 is an independent risk factor and independent of reactivity to human 
HSP60 (Mahdi et al. 2002).  
According to recent research results, HSPs are natural immune regulators. 
HSP60 has the capacity to act as a self-antigen and a foreign antigen and it can me-
diate both proinflammatory and anti-inflammatory signals (Quintana & Cohen 
2011). Self-HSP recognition can lead to an anti-inflammatory phenotype in T cells, 
where upregulated HSP in inflamed tissue can be target for HSP-specific regulatory 
T cells (Wieten et al. 2007). Self-HSP cross-reactive T cells are found to produce 
regulatory cytokines such as IL-10 (Zanin-Zhorov et al. 2006). In the case of 
chlamydial HSP60 immune responses, the regulatory T cell response has not been 
studied, but it is likely that chlamydial HSP60 and human HSP60 cross-reactive 
epitopes are recognized by regulatory T cells. In a study by Kinnunen et al., 30% of 
T cell clones isolated from salpingeal tissue of TFI patients recognized chlamydial 
HSP60 and when chlamydial HSP60-induced IL-10 and IFN-γ cytokine secretion 
was compared, 50% of T cell clones showed an IL-10-dominant response (Kinnunen 
et al. 2002a). By producing IL-10, HSP-reactive regulatory T cells may dampen the 
inflammatory response to Chlamydia and postpone infection resolution. On the other 
hand, it may also prevent excessive inflammation and subsequent tissue damage. 
2.4 Risk factors of disease pathogenesis 
Only some infected women develop late complications after C. trachomatis infec-
tion (Bakken & Ghaderi 2009). Several factors (host, pathogen and environment) 
affect the probability of infection transmission, persistence, ascension to the Fallo-
pian tubes and finally tissue remodeling and scarring, reflecting the clinical course 
of the disease and the risk of long-term complications. In general, C. trachomatis-
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induced fertility disorders in women result from tissue damage in the Fallopian tubes 
(Darville & Hiltke 2010). Therefore, factors that prevent ascension of bacteria to the 
Fallopian tubes lower the risk of tubal damage.  
2.4.1 Pathogens and environmental factors 
Factors such as infecting strain, normal flora, co-infections and hormonal status can 
affect infection transmission and bacterial ascension to the upper genital tract. Dif-
ferences in virulence have not been consistently associated with specific C. tra-
chomatis strains (Byrne 2010). Some serotypes seem to be more resistant to IFN-γ 
than others (Morrison 2000), which might influence virulence.  
Normal vaginal flora plays a role in defense and commonly includes Lactobacil-
lus spp., Gardnerella vaginalis, coagulase-negative staphylococci, Enterococcus 
spp., Ureaplasma urealyticum and E. coli. The lactobacilli metabolize glycogen 
released by vaginal epithelial cells to lactic acid, thus producing a low vaginal pH 
(3.5–5) (Quayle 2002). In vitro studies have demonstrated that this pH prevents the 
growth of C. trachomatis and thus may reduce the load of this pathogen in upper 
genital tract epithelium (Mahmoud et al. 1995). 
Bacterial vaginosis, which is characterized by a shift in vaginal bacterial flora 
and elevated pH, is, together with C. trachomatis or N. gonorrhoea infection, asso-
ciated with the development of PID (Paavonen et al. 1987). The altered microbial 
flora in cases of bacterial vaginosis often contains microbes that produce indole, 
such as Bacteroides species (DeMoss & Moser 1969), E. coli (DeMoss & Moser 
1969, Han et al. 2011) and Trichomonas vaginalis (Lloyd et al. 1991). Because geni-
tal strains of C. trachomatis are able to metabolize tryptophan of indole (Fehlner-
Gardiner et al. 2002), bacterial vaginosis might increase chlamydial resistance to 
host defense mechanisms (Batteiger et al. 2010). Co-infections with other pathogens 
can impair defense against C. trachomatis. In vitro, C. trachomatis enters a persis-
tent state in HSV-co-infected cells (Deka et al. 2006), suggesting that disease sever-
ity might be increased in individuals with concomitant infections. 
Hormones affect the mucosal epithelium (Patton et al. 2000) and therefore the 
phase of the menstrual cycle and oral contraceptive use can influence the transmis-
sion and spread of a pathogen. Prior to ovulation the cervical barrier is compro-
mised, as the mucus covering the cervix changes from viscous material to watery 
fluid to allow sperm penetration (Quayle 2002). This might also allow infection to 
ascend to the upper genital tract. However, upper genital tract infection is rare and it 
is possible that the temporary permeability is balanced by increased synthesis of 
antimicrobial molecules in the periovulatory period (Eggert-Kruse et al. 2000). Con-
traceptive use has been associated with an increased risk of C. trachomatis infection 
(Kimani et al. 1996, Morrison et al. 2009) but also with a reduced risk of acute 
salpingitis (Wolner-Hanssen et al. 1985) and clinical PID (Kimani et al. 1996).  
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2.4.2 Genetic factors of the host 
Host genetic factors probably play a role at all stages of infection from transmission 
to tissue repair and scarring (Morré et al. 2009). Diversity in genes that regulate the 
immune response, such as activation of CMI and IFN-γ production by CD4+ T cells, 
is likely to explain the interindividual differences in the course of infection. Diver-
sity in genes that are involved in tissue repair and scarring processes also probably 
contribute to clinical manifestation of pathogenesis.  
Genetically inherited factors affect to interindividual differences in susceptibility 
to and severity of infectious diseases. In the field of Chlamydia immunogenetics, 
Bailey et al. published a twin-study where the relative contribution of host genetics 
to the total variation of lymphoproliferative responses to C. trachomatis antigen was 
estimated. The study population consisted of 64 Gambian twin-pairs from trachoma 
endemic areas. Proliferative responses to serovar A EB antigens were measured in 
19 monozygotic twin pairs and 45 dizygotic twin pairs. They found a stronger corre-
lation and lower within-pair variability in the response in monozygotic compared 
with dizygotic twin pairs. The heritability estimate of variation in immune response 
was 0.39, suggesting that host genetic factors contributed almost 40% of the varia-
tion (Bailey et al. 2009).  
Several genetic association studies related to C. trachomatis genital and ocular 
diseases have been published (Tables 1 and 2). Candidate gene approaches have 
been used to study the genetic risk factors of susceptibility to and severity of C. 
trachomatis diseases. The studies have dealt with immunological regulation of in-
fection, concentrating on genes that code cytokines, PRRs, MHCs, which in humans 
are also called human leukocyte antigens (HLAs), and genes related to scarring and 
tissue repair such as those for matrix metalloproteinases. Immunogenetic studies 
related to C. trachomatis genital infections and ocular infections are listed in Tables 
1 and 2, respectively. However, comparison of the results of these studies is prob-
lematic because the study settings differ from each other in terms of case definition, 
classification of disease severity and selection of the control population.  
Mannose-binding lectin (MBL) low-producing genotypes have been associated 
with an increased risk of tubal pathology in two studies (Sziller et al. 2007, Laisk et 
al. 2010). Several HLA allele associations have been found in connection with infec-
tion susceptibility and disease complications. The HLA-DQB1*0602 genotype has 
been associated with C. trachomatis in two independent studies. This genotype is 
associated with disease susceptibility (Geisler et al. 2004) and with TFI (Kinnunen 
et al. 2002b). HLA-DQB1*06 has also been associated with recurrent C. trachoma-
tis infection (Wang et al. 2005b). 
In both ocular and sexually transmitted C. trachomatis infections the IL-10 cod-
ing IL10 gene has been associated with disease. As regards STIs, the IL10 -1082/-
819/-592 GCC haplotype is associated with a lower risk of recurrent infection 
(Wang et al. 2005b) and the IL10 -1082 AA genotype has been found to be more 
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common among TFI cases (37%) than in controls (25%). Together with HLA-
DQB1*0602 the IL10 -1082 AA genotype has been associated with TFI (p = 0.005) 
(Kinnunen et al. 2002b). In contrast, the IL10 -1082 GG genotype has been associ-
ated with an increased risk of trachoma in ocular infection. The opposite associa-
tions with IL10 -1082 SNP in genital and ocular infections might be due to differ-
ences in defense at different anatomical sites and differences in virulence of the STI 
and ocular strains. STI strains are more resistant to IFN-γ-mediated defense than 
ocular strains (Morrison 2000) and capable to synthesize tryptophan from indole 
provided by vaginal microbial flora (Caldwell et al. 2003, McClarty et al. 2007).  
Although the IL10 SNPs are associated with C. trachomatis disease, their roles in 
C. trachomatis-induced IL-10 production and regulation of the C. trachomatis-
specific immune response has not been studied in detail. In addition, information 
concerning other cytokine polymorphisms that regulate IFN-γ-mediated defense and 
interactions in the cytokine network is lacking. 
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3 Aims of the study 
The aim of this work was to identify immunogenetic factors associated with suscep-
tibility to and severity of C. trachomatis-induced tubal damage and to investigate 
how disease-related genetic markers affect phenotype, i.e. cytokine production and 
C. trachomatis-specific immune responses. 
 
Specific aims were: 
 
1) To define how immunosuppressive IL-10 and its genetic polymorphisms at the 
promoter site affect C. trachomatis-specific cytokine production and intensity of the 
cell-mediated immune response (I and III). 
2) To investigate the role of the IFN-γ-coding gene IFNG and other immune regula-
tory genes in susceptibility to and severity of Chlamydia-induced tubal damage (II). 
3) To study the interaction of IL-10 and IFN-γ cytokines and their genetic polymor-
phism in relation to C. trachomatis-specific immune responses (III). 
4) To study whether the IFN-γ expression-inducing cytokine IL-12 and its coding 
genes are associated with susceptibility to C. trachomatis-induced TFI or severity of 
tubal damage (IV). 
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4 Materials and methods 
4.1 Study subjects 
The study population included 164 TFI women (median age 33, range 23–40 years) 
with various degrees of tubal damage who attended the Infertility Clinic of the De-
partment of Obstetrics and Gynecology, Helsinki University Hospital during 1990–
2005 and had accurate laparoscopic evaluation of tubal damage. Of the 164 TFI 
cases 137 women had at least one positive immunological marker out of four (cell 
mediated immune response or antibodies to C. trachomatis or chlamydial HSP60) as 
an evidence of past C. trachomatis infection. The controls consisted of 176 female 
blood donors (median age 41, range 18–59 years) whose buffy coat specimens were 
provided by the Finnish Red Cross Blood Transfusion Service (Oulu, Finland) in 
2002 and 179 pregnant women (median age 36, range 27–44) from the Helsinki 
area, samples from whom were provided by the Finnish Maternity Cohort (FMC) 
serum bank collected in 2006. Blood donors were chosen as controls because they 
represent normal population and their blood cells are available for CMI studies. 
Pregnant women were chosen as controls because they represent fertile women and 
they were matched to the cases by age and residence. Unfortunately cells for CMI 
analyses were not available from these subjects. The study population also included 
17 women (median age 33, range 25–38) who were infertile for reasons other than 
TFI, such as male factor infertility, endometriosis, anovulation and unexplained 
infertility. These subjects were used in CMI analyses. A description of the study 
population subcohorts and their use in the original papers is shown in Table 3. 
The study protocol was approved by the Ethics Committee of the Department of 
Obstetrics and Gynecology, University Hospital, Helsinki, and the Finnish Red 
Cross Ethics Committee. Permission to link hospital register data to FMC data was 
obtained from the Ministry of Social Affairs and Health. The use of FMC samples 
was approved by the Institutional Ethics Committee and the FMC steering commit-
tee. 
4.1.1 Specimens  
The specimen types available in each subpopulation are shown in Table 3. With 
informed consent, peripheral blood samples were obtained from the study partici-
pants and transferred to the laboratory at room temperature. The specimens from 
pregnant women were delivered to the laboratory in regular vacuum tubes with no 
anticoagulant and therefore PBMCs were not available and blood clots were used as 
a source of DNA. 
Plasma was separated and stored at -20 ºC for antibody analysis. Peripheral 
blood mononuclear cells were isolated from heparinized blood by Ficoll–Paques 
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(Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation. The cells 
were washed three times with Hanks’ balanced salt solution (Sigma, St Louis, MO, 
USA) and suspended in RPMI 1640 medium (Sigma) containing 10% heat-
inactivated human AB serum (Finnish Red Cross, Helsinki, Finland) for LP assay 
and intracellular cytokine staining, or 5% fetal calf serum (FCS) for cytokine pro-
duction measurement. The rest of the cells were suspended in 60% AB serum/RPMI 
medium and stored at -150 ˚C. The leukocyte fraction was collected and used as a 
source of DNA for the genetic studies. 
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4.1.2 Definition of C. trachomatis-induced tubal damage 
Tubal damage was evaluated laparoscopically. In Studies II and IV the severity of 
damage was categorized according to the classification of Hull and Rutherford 
(Rutherford & Jenkins 2002) into three groups. The categories were: 
• Minor damage:  proximal or distal tubal occlusion but no tubal distension and at 
most, flimsy adhesions. 
• Moderate damage:  unilateral sactosalpinx or moderate tubal adhesions.  
• Severe damage: bilateral sactosalpinx or extensive adhesions. 
The immunity status to C. trachomatis infection was analyzed in TFI cases by 
measuring both CMI and antibody responses to C. trachomatis EB and to CHSP60. 
If at least one of four markers was found positive the subject was considered to have 
a history of C. trachomatis infection.  
4.2 DNA extraction 
Leukocyte fraction, blood clots and serum were used as DNA source material. From 
leukocytes the DNA was extracted by a guanidine hydrochloride method (Studies I, 
II, III and IV). DNA was extracted from blood clots by using a MagNA Pure LC 
instrument (Roche Diagnostics) and a DNA Isolation Kit - Large Volume (Roche 
Diagnostics), following the DNA LV Cells Protocol, and from serum by using a 
Total Nucleic Acid Isolation Kit – Large Volume (Roche Diagnostics), following 
the Total NA/LV Serum Plasma protocol (Studies II, III and IV). The quantity of 
DNA in serum samples was low and contributed to genotyping failure in some sam-
ples. 
4.3 Genotyping 
4.3.1 Conventional PCR (I) 
The IL10 promoter gene polymorphism of a single nucleotide at position -1082 
(A/G) was investigated by using a polymerase chain reaction (PCR) technique. Al-
leles were amplified in separate tubes with sequence-specific oligonucleotide prim-
ers, as published by Karhukorpi and Karttunen (Karhukorpi & Karttunen 2001). 
Polymerase chain reactions were performed in a total volume of 10 µl using ~ 100 
ng template DNA, 1 × PCR buffer (Promega, Madison, USA), 1.5 mmol/l MgCl2 
(Promega), 20 mmol/l of each nucleotide (Promega), 0.5 U Taq polymerase 
(Promega) and 0.25 mmol/l of each primer. After initial denaturation at 95 ºC for 5 
min, 30 cycles, consisting of denaturation for 30 s at 95 ºC  and annealing for 30 s at 
64 ºC were run. Final elongation was run for 6 min at 72 ºC. The PCR products were 
separated on 2% agarose gel and visualized under UV light illumination with ethid-
ium bromide stain. The results were documented photographically (Kodak DC 120 
Zoom). 
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4.3.2 Cytokine genotyping tray (II and III) 
Genotyping of cytokine polymorphisms (TNF -308 G/A [rs1800629], TGFB1 
codons 10 T/C [rs1982073] and 25 G/C [rs1800471], IL10 -1082 A/G [rs1800896], -
819 T/C [rs1800871] and -592 A/C [rs1800872], IL6 -174 G/C [rs1800795], IFNG 
+874 T/A [rs2430561]) was performed by PCR using a Cytokine Genotyping Tray 
(One Lambda Inc., Canoga Park, CA). Briefly, preoptimized primers, 19 µl of puri-
fied DNA, 1 µl of Taq polymerase (5 U/µl, manufactured for Applied Biosystems by 
Roche Molecular Systems Inc., Branchburg, New Jersey, USA) and buffer mix con-
taining deoxyribonucleoside triphosphate were used in PCR along with positive and 
negative controls, following the manufacturer’s instructions. The PCR products 
were separated on 2.5% agarose gel and visualized under UV light illumination with 
ethidium bromide stain. The results were documented photographically (Kodak DC 
120 Zoom).  
4.3.3 MALDI-TOF (IV) 
IL12A and IL12B SNPs were investigated by the Sequenom system using matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry 
(Bradic et al. 2011). Three SNPs of IL12A (rs2243123, rs583911 and rs568408) and 
seven of IL12B (rs3212227 i.e. 1188, rs1003199, rs11574790, rs919766, rs2569253, 
rs2853694 and rs6887695) genes were studied. 
4.4 Immune responses 
4.4.1 Antibody analysis 
Serum IgG antibodies specific to C. trachomatis and CHSP60 were analyzed using 
peptide-based ELISAs (Medac Diagnostika, Hamburg, Germany) according to the 
manufacturer’s instructions. Results were measured as absorbance at 450 nm, and 
OD > 0.4 was considered positive. 
4.4.2 Antigens used for cell-mediated immune response analysis 
Lymphocyte-stimulating antigens included EB antigens of C. trachomatis E and F 
serovars, representing the most prevalent inducers of C. trachomatis infection 
among the Finnish population. Lymphocyte proliferation (LP) assays were per-
formed using formalin-inactivated C. trachomatis strain E and F EB antigens at a 
total protein concentration of 0.6 μg/ml. Recombinant CHSP60 (kindly provided by 
professor Richard Morrison) was used at a protein concentration of 0.5 µg/ml. In 
Study I, formalin-inactivated C. pneumoniae serovar K7 EB was used as control 
antigen at a total protein concentration of 0.6 µg/ml. Pokeweed mitogen (12.5 µg/ml 
PWM, Gibco, Paisley, UK) served as a control mitogen for LP analysis. 
Cytokine measurement was performed using cell culture supernatants of PBMCs 
infected in vitro with viable C. trachomatis EB. Optimum numbers of chlamydial 
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EBs were determined for cytokine analysis in preliminary experiments with diluted 
EB stocks ranging from 2.0 to 0.002 IFU/ml. 
4.4.3 Lymphocyte proliferation 
The intensity of cell-mediated responses was analyzed by using conventional LP 
assays. Peripheral blood mononuclear cells were isolated from heparinized blood by 
Ficoll–Paques (Pharmacia Biotech, Uppsala, Sweden) density gradient centrifuga-
tion. The cells were washed three times with Hanks’ balanced salt solution (Sigma, 
St Louis, MO, USA) and suspended in RPMI 1640 medium (Sigma) containing 10% 
heat-inactivated human AB serum (Finnish Red Cross, Helsinki, Finland) for LP 
assays and intracellular cytokine staining, or 5% FCS for cytokine production meas-
urement.  
LP responses were studied by stimulation of 5 × 104 PBMCs/well in round-
bottomed 96-well plates in a total volume of 200 μl with and without antigen. The 
cultures were incubated in a humidified atmosphere of 5% CO2 at 37 °C for 6 days, 
and [methyl-3H]thymidine (0.2 μCi/well; Amersham Life Science, Buckingham-
shire, UK) was added to the cultures for the last 18 h of incubation. The LP re-
sponses were measured as counts per minute (cpm) of incorporated [methyl-
3H]thymidine by using a liquid scintillation counter (Wallac, Turku, Finland), and 
the results were expressed as median stimulation indices (SI = median cpm in the 
presence of antigen divided by median cpm in its absence) of triplicate cultures. The 
viability and reactivity of the cultured PBMCs were controlled in each experiment 
by requiring SI > 10 in response to the control Pokeweed mitogen. 
4.4.4 Cytokine production (I and III) 
The cytokines IL-2, IL-4, IL-5, IL-10, IFN-γ and TNF in Study I, and IL-10, IFN-γ 
and TNF in Study III were measured in infected and uninfected culture supernatants 
of 105 PBMCs/well. Human Th1/Th2 Cytokine Cytometric Bead Array kits (BD 
Biosciences, San Diego, CA, USA) were used in Study I and Cytokine Bead Array 
Flex Sets kits (BD Biosciences) were used in Study III according to the manufac-
turer’s instructions. The PBMC supernatant was collected after 2 days and stored at -
80 °C until analysis. The samples were analyzed by using a flow cytometer (FAC-
SCalibur, BD Biosciences) and the data was analyzed by using BD CellQuest and 
BD CBA software packages (Study I) and BD FCAP Array software (Study III). 
Cytokine concentrations are presented after subtraction of the background level 
(cytokine production by unstimulated cells). 
4.4.5  Effects of IL-10 and IFN-γ on the proliferative response (I) 
The effects of cytokines on LP were studied by adding recombinant human IL-10 
(0.25 pg/ml), IFN-γ (1 pg/ml) (R&D Systems, Minneapolis, MN, USA), or anti-IL-
10 neutralizing antibody (2.5 µl/1*106 cells) (clone JES3-9D7, Caltag, Burlingame, 
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CA, USA) to the PBMC cultures. Optimum concentrations of cytokines and neutral-
izing anti-IL-10 antibody were determined in preliminary experiments. Stimulation 
indices of infected cells (0.2 IFU/cell) were calculated in the presence and absence 
of cytokines or neutralizing anti-IL-10 antibody. The effect of an exogenous agent 
was expressed as a relative change of LP response to C. trachomatis infection in its 
presence compared with its absence.  
4.4.6 Intracellular cytokine analysis (I) 
Intracellular cytokine analyses were carried out on in vitro-infected or uninfected 
PBMC cultures using an immunofluorescence technique and BD Cytofix/Cytoperm 
kits (BD Biosciences). Brefeldin A containing BD Golgi-Plug solution was added to 
the PBMC cultures after 30 h of incubation to prevent the secretion of cytokines. 
After 10 h, the cells were stained for surface and intracellular antigens. The cell-
surface antigens were stained with PerCP-conjugated anti-CD3, PE-conjugated anti-
CD4 and FITC-conjugated anti-CD8 in the case of IFN-γ analysis and with PerCP-
conjugated anti-CD3 and APC-conjugated anti-CD14 in the case of IL-10 analysis. 
After fixation and permeabilization the intracellular cytokines were stained with 
FITC-conjugated anti-IFN-γ or PE-conjugated anti-IL-10 monoclonal antibodies. 
All antibodies and appropriate isotype control antibodies were purchased form BD 
Biosciences. Cells were measured in a FACS-Calibur cytometer. Cell populations 
were gated according to their surface antigens and cytokine production was deter-
mined in different subpopulations as percentage of cells staining positively for IFN-
γ and IL-10. 
4.5 Statistical analyses 
In Study I, Pearson’s Chi-Square test was used to compare genotype distributions in 
cases and controls. The Mann–Whitney U-test was used to compare cytokine pro-
duction and LP responses in different IL10 -1082 genotype groups and Wilcoxon’s 
signed-rank test was used to assess the effect of infection dose on the number of 
cytokine-producing cells and the effect of exogenous cytokine or neutralizing-anti 
IL-10 antibody on the relative change in C. trachomatis-specific LP responses. The 
analyses were performed by using SPSS for Windows 11.5 software (SPSS Inc., 
Chicago, IL, USA).  
In Studies II and IV, a χ2 test for trend was used to assess genotype distribution 
trends in cases and controls, and in cases with different degrees of severity of tubal 
damage (SPSS 15.0 and 18.0 software). The two-sample test of proportions was 
performed to compare genotype frequencies between cases and controls (Stata 5.0 
statistical software). Genotypes conferring susceptibility were presented in terms of 
odds ratios (ORs) with 95% confidence intervals (95% CIs). In Study II, Pearson’s 
Chi-Square test was used to test for differences in immunological markers between 
cases and controls (SPSS 15.0 software). In Study IV, Haploview 4.2 software (Bar-
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rett et al. 2005) was used to analyse the linkage disequilibrium (LD) between SNPs 
in IL12A and IL12B genes. 
In Study III, a test for trend was used to analyze the associations between IL10 
and IFNG polymorphisms and the intensities of immune responses (Stata 5.0 statis-
tical software). The Mann–Whitney U-test (SPSS 15.0 software) was used to ana-
lyze associations between two TNF genotype groups and immune responses. 
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5 Results 
5.1 C. trachomatis-specific immune responses in the study 
population 
Cell-mediated and humoral responses in different subcohorts of study populations 
are shown in Table 4. Serum IgG antibodies to C. trachomatis were 3- to 4-fold and 
IgG antibodies to chlamydial HSP60 were 3- to 5-fold more common among TFI 
cases than in other groups. Cell-mediated immune responses were also found at a 
significantly higher frequency among TFI cases than in other groups. Altogether, 26 
TFI cases were not reactive to the studied markers and were left out of genetic sus-
ceptibility analyses due to lack of evidence of C. trachomatis as an inductive factor 
in the development of tubal damage. 
Table 4. Humoral and cell-mediated C. trachomatis-specific immunity variables in 
                   different sample cohorts of the study population. 
Study population Immunity variables 
Tubal fac-
tor infertile 
women 
n (%) 
Female 
blood do-
nors 
n (%) 
Pregnant 
women 
 
n (%) 
Disease 
controls* 
 
n (%) 
IgG C. trachomatis 
      Negative 
      Positive 
 
69 (42.3) 
94 (57.7) 
 
39 (84.8) 
7 (15.2) 
 
145 (86.8) 
22 (13.2) 
 
13 (76.5) 
4 (23.5) 
IgG chlamydial HSP60 
      Negative 
      Positive 
 
73 (44.8) 
90 (55.2) 
 
41 (89.1) 
5 (10.9) 
 
135 (80.8) 
32 (19.2) 
 
14 (82.4) 
3 (17.6) 
SI C. trachomatis E 
      Negative 
      Positive 
 
19 (26.4) 
53 (73.6) 
 
77 (54.2) 
65 (45.8) 
 
N/A 
 
7 (41.2) 
10 (58.8) 
SI C. trachomatis F 
      Negative 
      Positive 
 
16 (30.8) 
36 (69.2) 
 
73 (51.4) 
69 (48.6) 
 
N/A 
 
10 (58.8) 
7 (41.2) 
SI CHSP60 
      Positive 
      Negative  
 
39 (54.2) 
33 (45.8) 
 
104 (73.2) 
38 (26.8) 
 
N/A 
 
12 (70.6) 
5 (29.4) 
* Women infertile for reasons other than tubal factor infertility 
SI: stimulation index 
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The intensity of response differed between TFI cases and controls. LP responses 
were similar in the studied serovars, C. trachomatis E and F, and the responses were 
higher among TFI cases (median response to E 16.9; 25–75% percentiles 5.2–49.5 
and F 14.0; 4.4–36.7) than in blood donors (median response to E 3.7; 25–75% per-
centiles 1.1–21.5 and F 4.5; 1.3–24.8). The median LP response to chlamydial 
HSP60 antigen was 2.1 (25–75% percentiles 0.8–7.5) among TFI cases and 0.9 
(0.4–2.7) among blood donors. Differences in all studied variables were statistically 
significant (p<0.005). In addition, levels of antibodies against both C. trachomatis 
EB and chlamydial HSP60 antigens were higher among TFI cases than in other 
groups (between TFI and pregnant women or female blood donors, p<0.001; be-
tween TFI cases and disease controls, i.e. women infertile for reasons other than 
TFI, p<0.01). 
5.2 Cytokine polymorphisms and susceptibility to C. trachomatis- 
induced TFI 
The association between selected polymorphisms and susceptibility to and severity 
of C. trachomatis-induced tubal damage was studied. In Study II the roles of IL10 -
1082, -819, -592, IFNG +874, TNF -308, TGFB1 codons 10 and 25 and IL6 -174 
cytokine SNPs were studied among 114 laparoscopically verified TFI cases and in 
176 female blood donors as controls.   
In Study IV the roles of IL12A and IL12B genes were studied in an enlarged 
study population. The population consisted of 163 TFI cases and 179 pregnant 
women who served as controls. Altogether, 26 TFI cases did not have an immune 
marker of past C. trachomatis infection and were excluded. Due to a low quantity of 
DNA in some samples, genotyping failures accumulated in some subjects. The sub-
jects with three or more missing SNP genotypes (54 controls and 37 TFI cases) were 
excluded from genetic association analysis and the final study population contained 
125 controls and 100 TFI cases. The overall genotyping success as regards IL12A 
and IL12B SNPs in the final study population was 83.6–99.6% depending on the 
SNP. 
In Study II 96 of 137 (84.2%) TFI cases and in Study IV 137 of 163 (84.0%) TFI 
cases had at least one immune marker (cell-mediated or antibody response to C. 
trachomatis EB or CHSP60) as evidence of past C. trachomatis infection and were 
included in the genetic susceptibility analysis. The genotype distribution of selected 
polymorphisms is shown in Table 5. Among the controls, all studied polymorphisms 
were in Hardy–Weinberg equilibrium (HWE), except for IL10 -1082 (p = 0.042). 
Among the TFI cases two of the studied IL12B SNPs, rs11574790 (p = 0.001) and 
rs919766 (p = 0.004), which exhibited strong linkage disequilibrium (Figure 3), 
were not in HWE in the TFI cases. 
The IL6 -174 CC genotype was more common in the TFI cases than in the con-
trols (36.8% vs. 24.4%, p = 0.03). Although the controls differed from HWE, the 
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IL10 -1082/-819/-592 ATA/ATA genotype was found more commonly among TFI 
cases than in controls (OR = 5.04, 95% CI 1.17–21.63).  
A divergent genotype distribution was found between cases and controls in con-
nection with the IL12B 1188 (p for trend = 0.028). The minor allele C was rare; 
among TFI cases no CC homozygotes were found. The AC genotype was more 
common in the TFI women than in the controls (p = 0.009) and was associated with 
an increased risk of TFI (OR = 2.44, 95% CI = 1.23–4.87). 
 
 
 
Figure 3. Linkage disequilibrium (LD) maps for the markers genotyped in the IL12A 
and IL12B genes created with Haploview program (Barrett et al. 2005). 
Black squares represent high LD; white squares represent low LD. Loca-
tions of single nucleotide polymorphisms are shown. Recall that rs3212227 
is IL12B 1188. 
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Table 5. Distribution of cytokine genotypes in chlamydial TFI compared with controls. In 
Study II, the study population consisted of 96 cases with chlamydial TFI 
compared with 176 female blood donors as controls. In Study IV, the study 
population for genetic association analysis consisted of 100 TFI cases and 125 
pregnant women as controls. The two-sample test of proportions was performed 
to compare the genotype frequencies between cases and controls. A χ2 test for 
trend was used to investigate a possible trend between disease and genotype. 
Genotypes conferring susceptibility are represented by odds ratios (ORs) with 
95% confidence intervals (95% CIs). 
No. of genotypes (%)         Genotype 
TFI 
women 
Controls 
Test of 
propor-
tion, p 
value 
χ2 for 
trend, 
p value 
OR (95% CI) 
IL10 -1082/-819/-592  
promoter (II) 
        GCC/GCC (high) 
        GCC/ACC (intermediate) 
        GCC/ATA (intermediate) 
        ACC/ACC (low) 
        ACC/ATA (low) 
        ATA/ATA (low) 
 
 
19 (19.8) 
32 (33.3) 
17 (17.7) 
7 (7.3) 
14 (14.6) 
7 (7.3) 
 
 
41 (23.3) 
60 (34.1) 
42 (23.9) 
13 (7.4) 
17 (9.7) 
3 (1.7) 
 
 
0.505 
0.900 
0.239 
0.977 
0.222 
0.019 
 
 
0.053 
 
 
 
Reference 
1.15 (0.58-2.30) 
0.87 (0.40-1.91) 
1.16 (0.40-3.38) 
1.78 (0.73-4.34) 
5.04 (1.17-21.63) 
IFNG +874 intron 1 (II) 
        TT (high) 
        TA (intermediate) 
        AA (low) 
 
12 (12.5) 
48 (50.0) 
36 (37.5) 
 
21 (12.0) 
85 (48.6) 
69 (39.4) 
 
0.904 
0.822 
0.755 
 
0.773 
 
Reference 
0.99 (0.45-2.18) 
0.91 (0.40-2.06) 
TNF -308 promoter (II) 
        GG (low) 
        GA (high) 
        AA (high) 
 
68 (70.8) 
28 (29.2) 
0     
 
127 (72.2) 
45 (25.6) 
4 (2.3) 
 
0.817 
0.522 
0.138 
 
0.898 
 
Reference 
1.16 (0.67-2.03) 
- 
IL6  -174 promoter (II) 
        GG (high) 
        GC (intermediate) 
        CC (low) 
 
22 (23.2) 
38 (40.0) 
35 (36.8) 
 
42 (23.9) 
91 (51.7) 
43 (24.4) 
 
0.896 
0.066 
0.031 
 
0.154 
 
Reference 
0.80 (0.42-1.51) 
1.55 (0.79-3.07) 
IL12B, 1188 3’UTR (IV) 
        AA 
        AC 
        CC 
 
66 (69.5) 
29 (30.5) 
0 (0) 
 
89 (84.0) 
16 (15.1) 
1 (0.9) 
 
0.015 
0.009 
0.343 
 
0.028  
 
Reference 
2.44 (1.23-4.87) 
- 
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5.3 Cytokine polymorphisms and severity of C. trachomatis-
induced tubal damage 
The TFI cases were categorized into three groups according to the severity of tubal 
damage, following the classification of Hull and Rutherford (Rutherford & Jenkins 
2002). In Study II minor damage with proximal or distal tubal occlusion but no tubal 
distension and flimsy adhesions at most was found in 20 out of 96 (20.8%) cases 
with C. trachomatis-induced TFI, moderate damage with unilateral sactosalpinx or 
moderate tubal adhesions in 42 (43.8%) cases, and severe damage with bilateral 
sactosalpinx or extensive adhesions in 34 (35.4%) cases. In Study IV, minor damage 
was found in 24 of 100 (24.0%) cases, moderate damage in 41 (41.0%) cases, and 
severe damage in 35 (35.0%) cases. 
The relationships between cytokine genotypes and the degree of tubal damage 
are shown in Table 6. The IL10 -1082 A allele was associated with disease severity 
(p for trend = 0.03). The IL10 -1082 AA and AG genotypes were associated with 
increased risks of moderate (OR = 5.33; 95% CI = 1.07–26.61 and OR = 2.67; 95% 
CI = 0.74–9.59 respectively) and severe (OR = 7.33; 95% CI = 1.27–42.29 and OR 
= 4.22; 95% CI = 1.00–17.80 respectively) tubal damage. 
A trend towards increasing damage in the presence of the TNF -308 A allele was 
observed (p for trend = 0.036). The TNF -308 A allele was found in 15.0% of the 
cases with minor damage, 26.2% of the cases with moderate damage and in 41.2% 
of the cases with severe tubal damage. The TNF -308 GA genotype was associated 
with increased risks of moderate (OR = 2.01; 95% CI = 0.49–8.21) and severe (OR 
= 3.97; 95% CI = 0.97–16.16) tubal damage compared with women with milder 
disease. The TNF -308 A/G SNP was associated with both the severity of adhesions 
(p for trend = 0.025) and sactosalpinx (p for trend = 0.029). 
The IL12B 1188 A/C SNP, which was associated with disease susceptibility was 
also linked to disease severity (p for trend=0.008) when compared with controls. 
The AC and CC genotypes were combined because of the small number of CC ho-
mozygotes. The subjects carrying allele C had increased risks of moderate (OR = 
1.45, 95% CI = 1.06–5.95) and severe tubal damage (OR = 2.73, 95% CI =1.15–
6.52) compared with pregnant women. When compared with minor damage a statis-
tically significant risk was not found because of the small sample size (Table 6).  
The distribution of the TGFB codon 25 genotype was not analyzed because the 
number of cases with a codon 25 C allele was small. The distribution of IFNG +874, 
IL6 -174 and TGFB1 codon 10 genotypes was similar among cases with different 
degrees of tubal damage. These polymorphisms were not associated with disease 
severity. 
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5.4 Genetic variability in C. trachomatis-specific immune 
responses 
To better understand the genetic associations with susceptibility to and severity of 
tubal damage we studied genotypes in relation to C. trachomatis-induced immune 
responses (Studies I and III). 
5.4.1 Cytokine polymorphisms and in vitro cytokine production 
In Study I the role of the IL10 -1082 polymorphism on IL-10 secretion, and indi-
rectly on secretion and balance of type 1 and type 2 cytokines was studied by meas-
uring type 1 (IL-2, IFN-γ and TNF) and type 2 (IL-4, IL-5 and IL-10) cytokines in 
culture supernatants of PBMCs infectedin vitro . The experiments were performed in 
connection with 33 individuals who represented different IL10 -1082 genotypes (11 
AA, 17 AG and 5 GG) and who were selected on the basis of their positive LP re-
sponses to chlamydial EB. C. trachomatis (0.002 IFU)-induced IL-4 and IL-5 re-
sponses did not significantly differ from background levels (<13.2 pg/ml for IL-5 
and <5.5 pg/ml for IL-4). C. trachomatis-induced IL-2 production differed clearly 
from the background level, although the concentrations were relatively low (3.1–
29.0 pg/ml for C. trachomatis and 0.5–20.3 pg/ml for background, p<0.001).   
In Study III the roles of cytokine SNPs in quantitative secretion of IL-10, IFN-γ 
and TNF were evaluated by analyzing the secreted cytokines in culture supernatants 
of C. trachomatis-infected (0.01 and 1 IFU/lymphocyte) and uninfected PBMCs. 
The study population consisted of 139 women with no selection based on LP re-
sponses. C. trachomatis infection induced significantly greater secretion of each 
cytokine compared with spontaneous secretion from uninfected lymphocytes 
(p<0.001), and the secretion was dose-dependent. Levels of IL-10 and IFN-γ pre-
sented in the following analysis are those induced by 1 IFU/lymphocyte, with the 
cytokine levels in uninfected lymphocytes subtracted. 
5.4.1.1 IL10 polymorphisms 
In Study I we found that C. trachomatis-induced IL-10 secretion was stronger 
among subjects with the IL10 -1082 GG genotype (median IL-10 production 12702 
pg/106 monocytes) than in those with the AG (3782 pg/106 monocytes) or AA geno-
type (4437 pg/106 monocytes; p<0.001) and variation was greatest in connection 
with the AG genotype. IL-10-induced Th1 downregulation was reflected in produc-
tion of proinflammatory cytokines and C. trachomatis-induced IFN-γ and TNF se-
cretion was clearly stronger in subjects with the AA (median IFN-γ production 356 
pg/106 lymphocytes and TNF 1740 pg/106 monocytes) genotype compared with 
those with the AG (86 pg/106 lymphocytes and 1356 pg/106 monocytes) or GG 
genotype (0 pg/106 lymphocytes and 0 pg/106 monocytes, respectively; p<0.05). 
Concentrations of IL-2 also tended to be higher with the IL10 -1082 AA genotype 
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than in those with the GG genotype, although the difference was not statistically 
significant (Figure 4). 
In Study III the IL10 polymorphism study was extended to cover the IL10 -
1082/-819/-592 haplotype in a larger study population. C. trachomatis-induced IL-
10 production was found to vary slightly between the subjects with different geno-
types. IL10 -1082/-819/-592 form three haplotypes: GCC, ACC and ATA. A linear 
trend between secreted IL-10 levels and the studied IL10 haplo-genotypes suggested 
that the GCC haplotype elicits the strongest IL-10 production, the ACC haplotype 
intermediate production and the ATA haplotype the lowest production (p for trend 
=0.06) (Figure 5A). 
 
 
 
Figure 4. C. trachomatis-induced production of IL-10, TNF, IFN-γ and IL-2 cytokines 
(pg/1 × 106 cells) in subjects with IL10 -1082  AA, AG and GG genotypes. 
Statistical differences between AA and GG genotype groups are shown. 
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5.4.1.2 IFNG and TNF polymorphisms 
C. trachomatis-induced IFN-γ levels tended to be highest in the subjects with the 
IFNG +874 TT genotype (median 45.3 and 25–75% percentiles 22.9–308.0), inter-
mediate in subjects with the TA genotype (53.3 and 14.8–199.5) and lowest in sub-
jects with the AA genotype (30.8 and 6.7–122.2), although the trend was not statisti-
cally significant (p=0.06) (Figure 6A). 
An association between the TNF -308 G/A genotype and spontaneous TNF se-
cretion was detectable in cell culture supernatants of unstimulated cells (p=0.03). 
Secretion of TNF was higher in the women carrying the A allele (GA or AA geno-
type) than in the women with the TNF -308 GG genotype (median 68.6 pg/ml; 25–
75% percentiles 26.7–125.6 vs. 29.2; 9.0–96.8 pg/ml; p = 0.031). TNF secretion 
increased after infection with 0.01 IFU/cell (GA or AA 132.9; 93.1–225.4 versus 
GG 97.8; 58.5–155.8 pg/ml; p=0.043) or 1 IFU/cell (GA or AA 634.0; 377.7–895.0 
versus GG 679.2; 452.3–1134.6 pg/ml; p = 0.121), but linkage between TNF levels 
and TNF -308 genotypes was not detectable after subtracting the spontaneous secre-
tion of TNF.  
5.4.2 Cytokine polymorphisms and lymphocyte proliferative responses 
The relationships between the cytokine SNPs and C. trachomatis-specific cell-
mediated immune responses were analyzed in the subjects in the different genotype 
groups by using LP assays. Controls and cases were combined in analysis of asso-
ciations between genetic factors and intensity of the immune response because the 
genetic effect was found to be parallel in all groups. 
The IL10 -1082/-819/-592 SNPs were associated with the intensity of LP re-
sponses to C. trachomatis serotypes E and F as well as to chlamydial HSP60 (Figure 
5B). These SNPs form three haplotypes – GCC, ACC and ATA – and the IL10 -819 
and -592 SNPs are in perfect linkage disequilibrium, i.e. they form only two haplo-
types, TA and CC. The IL10 -1082 and IL10 -819/-592 SNPs were analyzed sepa-
rately to evaluate their contribution to regulation of LP responses. A significant 
association was found between LP responses to all chlamydial antigens and the IL10 
-1082 SNP (p<0.03), but not the IL10 -819/-592 SNPs. 
The relationship between the IFNG +874 (T/A) polymorphism and C. trachoma-
tis-induced LP responses was less evident than that concerning the IL10 polymor-
phisms. The LP responses to all antigens were greatest in the subjects with the IFNG 
+874 TT genotype and lowest among the subjects with the IFNG +874 AA genotype 
(Figure 6B). The trend was statistically significant as regards the C. trachomatis F 
antigen (p = 0.05). The TNF -308 polymorphism was not associated with the inten-
sity of LP responses. 
The combined effect of IL10 and IFNG polymorphisms was analyzed to evaluate 
the interaction of these SNPs in C. trachomatis-specific cell-mediated responses. To 
enhance the power of statistical analysis, the subjects were sub-grouped into six 
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groups according to the IL10 -1082 genotype and by the presence of a high- (TT or 
TA) or low-producing IFNG genotype (AA). As shown in Figure 7, subjects who 
are genetically predisposed to high IFN-γ and low IL-10 secretion (AA genotype) 
had the highest LP responses to the C. trachomatis antigens and, vice versa, the 
subjects who tend to produce high levels of IL-10 and low levels of IFN-γ had the 
lowest LP responses (p for trend: C. trachomatis E = 0.01, F = 0.01 and chlamydial 
HSP60 = 0.04). 
 
 
 
Figure 5. IL10 -1082(A/G)/-819(C/T)/-592(C/A) polymorphism and C. trachomatis-
specific immune responses. A) Production of IL-10 in different IL10 geno-
type groups (p for trend = 0.06). B) LP responses to C. trachomatis E (p = 
0.04), F (p = 0.01) and chlamydial HSP60 (p = 0.04) antigens in different 
IL10 genotype groups. 
 
 
 
 
 
A B 
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Figure 6. IFNG +874 (T/A) polymorphism and C. trachomatis-specific immune re-
sponses. A) Production of IFN-γ in different IFNG genotype groups. The 
cells were infected with 1 IFU/cell; p for trend = 0.06. B) LP responses to C. 
trachomatis E (p for trend = 0.13), F (p = 0.05) and chlamydial HSP60 
(CHSP60) (p = 0.85) antigens in different IFNG genotype groups. 
 
 
 
Figure 7. Combined effect of IL10 and IFNG polymorphisms on proliferative re-
sponses to C. trachomatis E (p for trend <0.01), F (p<0.01) and chlamydial 
HSP60 (CHSP60) (p<0.04) antigens. The subjects were sub-grouped into 6 
genotype groups according to the IL10 -1082 genotype and by the pres-
ence of high- (1 or 2 copies of the IFNG +874 T allele) or low-producing 
IFNG genotypes (IFNG +874 AA). 
A B
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5.5 C. trachomatis infection in vitro and biological 
characteristics of IL-10 and IFN-γ 
5.5.1 IL-10- and IFN-γ-producing cells 
In order to study the role of monocytes and CD4+ and CD8+ T cells as regulators of 
the immune response we analyzed intracellular IL-10 and IFN-γ production in C. 
trachomatis-infected cells by using an immunofluorescence technique and flow 
cytometry. Analysis of CD4+/CD3+ and CD8+/CD3+ T cells revealed that the me-
dian percentage of IFN-γ-secreting cells was higher among CD4+ (median 12.6%) 
than among CD8+ (median 4.8%) T cells (Study I). However, a statistically signifi-
cant increase compared with uninfected cells was found in both T-cell subgroups. 
A significant increase of IL-10-secreting CD14+ monocytes was detected in C. 
trachomatis-infected cells compared with uninfected cells (Study I), but there was 
only a marginal increase in IL-10-secreting CD3+ cells.  
5.5.2 Influence of exogenous IL-10 and IFN-γ on C. trachomatis-specific 
cell responses 
The influence of the cytokines IL-10 and IFN-γ on C. trachomatis-induced CMI 
responses was further studied by co-culturing PBMCs in the presence of recombi-
nant IL-10 and IFN-γ. As expected, adding exogenous IFN-γ supported and adding 
exogenous IL-10 inhibited the LP responses (Figure 8). When IL-10 was blocked by 
adding anti-IL-10 antibody, LP responses increased in all genotype groups. The 
relative change in LP response increased most in the GG group, but because of the 
low number of subjects, it did not reach statistical significance. However, the re-
sponses remained lower than in the AA group. 
 
Figure 8. Relative change in PBMC proliferative responses to C. trachomatis infec-
tion in the presence of exogenous IFN-γ, IL-10 or IL-10 neutralizing anti-IL-
10 antibody. The relative change is expressed as a ratio of the LP re-
sponse to C. trachomatis antigen in the presence of exogenous agent to 
the LP response in its absence. 
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6 Discussion 
The aim of this study was to identify immunogenetic risk factors of tubal damage 
and their functional effects on C. trachomatis-specific cell-mediated immune re-
sponses. The results show that variation in certain cytokine-coding genes is associ-
ated with disease susceptibility and also with interindividual differences in the inten-
sity of cell-mediated immune responses. 
6.1 Main findings 
6.1.1 Effect of IL10 polymorphisms (I and III) 
Our studies showed that the IL10 -1082 A allele increases the risk of severe tubal 
damage. This allele and the AA genotype have also been associated with susceptibil-
ity to TFI (Kinnunen et al. 2002b) and recurrent C. trachomatis infections (Geisler 
et al. 2004). IL-10 acts as a strong anti-inflammatory mediator (Moore et al. 1993) 
and its effect on proinflammatory cytokine production and the intensity of lympho-
cyte proliferation was also seen in our studies. 
Of the IL10 -1082, -819 and -592 polymorphisms studied in this work, the IL10 -
1082 SNP is most strongly associated with the intensity of LP responses against C. 
trachomatis antigens. The IL10 -819/-592 SNPs play a minor role in the regulation 
of C. trachomatis-induced LP responses. Our results indicate that on the basis of 
IL10 -1082 genotypes, C. trachomatis-induced immune responses could be divided 
into those with low IL-10 secretion and clearly positive LP responses, and those 
with high IL-10 secretion and diminished LP, IFN-γ and TNF responses. The central 
inhibiting role of IL-10 was confirmed by neutralizing IL-10 with specific anti-IL-
10 antibody in cell culture. Enhanced lymphocyte proliferation responses were then 
observed in the cells from the study subjects and the increase was greatest among 
high IL-10 producers with the IL10 -1082 GG genotype. Addition of recombinant 
IFN-γ was not able to prevent inhibition of LP responses, suggesting a dominant role 
of IL-10.  
The influence of the IL10 -1082 genotype on LP responses was similar with all 
studied antigens (C. trachomatis E and F, CHSP60 and C. pneumoniae) and among 
different study populations. Thus, the IL10 -1082 genotype association with CMI 
response probably reflects the type of immune response in the presence of an intra-
cellular microorganism. A similar association between IL10 polymorphism and LP 
responses has been reported in connection with helminth antigen (Timmann et al. 
2004).  
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6.1.2 Effect of IFNG +874 polymorphism (II and III) 
Statistically significant association between IFNG +874 polymorphism and chlamy-
dial TFI was not found. This might have been the result of small sample size. More 
cases with severe tubal damage had the genotype IFNG +874 AA than cases with 
milder damage. We also found that subjects with this IFNG +874 AA genotype 
tended to have lower LP responses compared with other IFNG +874 genotype 
groups and although not statistically significant, the quantitative secretion of IFN-γ 
was in line with the LP responses, the highest levels being observed in the subjects 
with the IFNG +874 TT genotype and the lowest levels in those with the AA geno-
type.  
IFN-γ is necessary for protection against C. trachomatis infection (Rottenberg et 
al. 2002, Gondek et al. 2009) and deficiency in IFN-γ production is postulated to 
promote persistent C. trachomatis infection (Beatty et al. 1993). IFN-γ can limit C. 
trachomatis infection directly through a variety of mechanisms including induction 
of tryptophan catabolism and NO production (Loomis & Starnbach 2002), or indi-
rectly by augmenting host immune responses (Boehm et al. 1997). Our results show 
that the indirect influence of IFN-γ is significant and higher IFN-γ levels among 
subjects with the IFNG +874 AA genotype are associated with enhanced intensity of 
the LP response compared with other genotype groups. IFN-γ upregulates the ex-
pression of MHC I and MHC II antigens, leading to enhanced presentation of mi-
crobial antigens to both CD4+ and CD8+ T cells (Boehm et al. 1997), and thereby 
an increased LP response. 
Our results also fit in with the association between the IFNG +874 A allele and 
poor outcome in many intracellular infections, as described by others (Rossouw et 
al. 2003, Liu et al. 2006, Rasouli & Kiany 2007). The IFNG +874 A allele also lies 
within the disease-associated haplotype in trachoma, suggesting that less efficient 
IFN-γ production may be associated with trachomatous scarring (Natividad et al. 
2005). We found a link between the IFNG +874 SNP and C. trachomatis-induced 
LP responses, but we did not find an association with disease or with IFN-γ produc-
tion (p for trend = 0.06). This might be due to small sample size, but on the other 
hand, IFN-γ may also have a less important role in host defense during genital C. 
trachomatis infection than during ocular infections or many other intracellular infec-
tions, because genital C. trachomatis strains are less sensitive to IFN-γ-mediated 
defense (Morrison 2000). This is based on the capability of genital C. trachomatis 
strains to synthesize tryptophan from indole provided by vaginal microbial flora 
(Caldwell et al. 2003, McClarty et al. 2007).  
6.1.3 Joint effect of IL10 and IFNG polymorphisms (III) 
According to our results, the combination of IFNG +874 and IL10 -1082 genotypes 
has a cumulative effect on the intensity of C. trachomatis-induced LP responses. 
The subjects genetically predisposed to high IFN-γ (IFNG +874 TT or TA genotype) 
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and low IL-10 secretion (IL10 -1082 AA genotype) had the highest LP responses to 
the C. trachomatis antigens and, vice versa, the subjects who tend to produce high 
levels of IL-10 and low levels of IFN-γ had the lowest LP responses. However, the 
IL10 -1082 effect on LP responses was clearly stronger, indicating that genetic pre-
disposition to abundant IL-10 secretion dominates over IFN-γ secretion in subjects 
with any IFNG +874 genotype.  
The great variation in LP responses in subjects with a low IL-10- and a high IFN-
γ-producing phenotype (Figure 7) suggest that these subjects have efficient IFN-γ-
mediated protection when exposed to C. trachomatis. The results are consistent with 
those in our experiment in which addition of recombinant IFN-γ increased LP re-
sponses in low IL-10 producers but had little effect on the response in high produc-
ers (Figure 8). 
6.1.4 Effect of TNF polymorphisms (II and III) 
Chlamydia infection induces TNF secretion in human lymphocytes (Study I) and in 
Fallopian tube organ cultures (Ault et al. 1996). Because TNF is involved in fibrosis 
and tissue remodeling (Banno et al. 2004) and the presence of the TNF -308 A allele 
has been shown to increase the risk of scarring trachoma (Conway et al. 1997), this 
SNP was an interesting candidate as regards an association between C. trachomatis 
and TFI. 
We found that carrying the TNF -308 A allele was associated with a risk of mod-
erate and severe adhesions in TFI. However, when we studied the role of this SNP in 
C. trachomatis-induced cytokine production and LP response the results were am-
biguous. In addition, the literature covering the role of the TNF -308 polymorphism 
in TNF production is inconsistent (Bayley et al. 2004) and the stimulus and studied 
cell type can affect TNF expression (Kroeger et al. 2000). Our results were some-
what discrepant, and infection dose-dependent. We found that cells from women 
carrying the A allele showed elevated levels of TNF in culture supernatants of un-
stimulated cells and in supernatants after infection with 0.01 IFU/cell, compared 
with women with the GG genotype. However, the association was not found after 
subtraction of spontaneous secretion of unstimulated cells, suggesting that C. tra-
chomatis-induced TNF production is independent of the TNF -308 SNP, although 
this SNP is linked to the initial TNF level and could affect the development of the 
immune response at a very early stage of infection.  
The involvement of TNF in pathology has been demonstrated in many inflamma-
tory diseases (Clark 2007), in genital Chlamydia infection in mice (Perfettini et al. 
2000) and in human trachoma (Conway et al. 1997). Although it is tempting to 
speculate that carrying the A allele could increase TNF secretion and thus increase 
the risk of severe tubal damage after C. trachomatis infection, the association be-
tween TNF -308 genotypes and TNF production needs to be studied further. In this 
investigation the sample size was relatively small for a quantitative study, consider-
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ing that the A allele is uncommon – in our material there were only four AA homo-
zygotes (Table 5). It is also possible that the association with disease manifestation 
is derived from a gene nearby that is linked to TNF, because the gene lies in an 
MHC III area which exhibits extensive linkage disequilibrium. Trachoma studies 
indicate that the TNF -308 A marker is part of a more complex picture. The TNF 
locus and also related neighboring genes such as that for lymphotoxin alpha affect 
the risk of severe outcome in ocular C. trachomatis infection (Natividad et al. 2007). 
6.1.5 Effect of IL12A and IL12B polymorphisms (IV) 
We found that one of the studied IL-12-related SNPs, IL12B 1188 A/C, was associ-
ated with TFI and the severity of tubal damage. This SNP is recognized as a suscep-
tibility correlate in many inflammatory conditions from infections to autoimmune 
diseases (Cargill et al. 2007, Nair et al. 2008, McGovern et al. 2009, Phawong et al. 
2010, Wang et al. 2010). The other SNPs studied were not associated with suscepti-
bility to TFI or severity of tubal damage.  
C. trachomatis infection increases endocervical IL-12 production in vivo (Wang 
et al. 2005a), indicating that IL-12 has an active role in the immune cascade pro-
voked by C. trachomatis. The SNP IL12B 1188 A/C has also been associated with 
recurrent C. trachomatis infections (Geisler et al. 2010). In particular, the minor 
allele C, which in our data increased the risk and severity of TFI, was associated 
with recurrent C. trachomatis infections. As repeated infections and continuous 
inflammation increase the risk of tubal damage, our findings are in agreement with 
those reported by Geisler et al. In contrast, in inflammatory autoimmune illnesses 
such as psoriasis and Crohn’s disease, the common genotype AA has been linked to 
disease susceptibility (Cargill et al. 2007, Nair et al. 2008, McGovern et al. 2009). 
The results suggest that IL12B is involved in the disease process, but more data is 
needed to investigate the mechanism behind the genotype association. Differences in 
IL12B may be reflected in individual variation in levels of IL-12 and IL-23 cytoki-
nes, which are composed of a common IL-12p40 and distinct IL-12p35 or IL-23p19 
subunits, respectively. The IL-12 effect is mediated through the IFN-γ pathway nec-
essary in defense against C. trachomatis. The effects of IL-23 are less well known, 
but it seems to play a key role in the induction of Th17 cells. These cells induce 
production of proinflammatory cytokines and might be responsible for the inflam-
mation-driven pathogenesis, rather than the Th1 subset (Goriely et al. 2009). Besides 
effects mediated through IL-12 and IL-23, it is also possible that IL-12p40 has bio-
logical activity on its own, as it has been reported that IL-12p40 can act as an an-
tagonist of IL-12 in vitro (Zhang & Wang 2008) and thus mediate an anti-
inflammatory effect. This hypothesis is also supported by Müller-Berghaus et al. 
(Müller-Berghaus et al. 2004), who showed that elevated levels of IL-12p40 were 
associated with lower levels of IL-12p70. 
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Although the mechanism behind the connection is still unsolved, the disease as-
sociations and the literature (Cargill et al. 2007, Nair et al. 2008, McGovern et al. 
2009, Geisler et al. 2010) suggest that IL12B 1188 allele C is linked with a weaker 
and allele A with a stronger inflammatory response. Subjects with the AA genotype 
seem to cope with C. trachomatis infection better than subjects who carry allele C. 
This might be a result of more efficient Chlamydia clearance, and also protective 
immunity. The results may explain some individual variations in the manifestations 
of C. trachomatis disease. Further studies dealing with IL12B polymorphism and the 
immune response are needed to reveal the mechanism behind the disease association 
and to increase understanding of the pathogenesis of the disease, which is needed in 
the design of new therapeutic strategies. 
6.1.6 IL-10- and IFN-γ-producing cells (I) 
We found that both CD4+ and CD8+ cells seem to secrete IFN-γ, which is in accor-
dance with animal data (Stagg et al. 1998, Igietseme et al. 2002). The number of IL-
10-secreting CD3+ T cells increased marginally following C. trachomatis infection. 
This is in line with the results of a study by Kinnunen et al. in which IL-10-secreting 
C. trachomatis-specific T cells were occasionally detected in inflamed salpingeal 
tissue (Kinnunen et al. 2002a). However, IL-10 secretion predominantly originated 
from CD14+ monocytes, suggesting that the role of IL-10-secreting T cells in the 
course of TFI pathogenesis is less important than that of CD14+ monocytes. Their 
influence is especially strong among subjects with the IL10 -1082 GG genotype. 
6.2 Methodological considerations and limitations of the study 
6.2.1 Study population 
The study population consisted of TFI-cases, female blood donors, pregnant women 
and women infertile for reasons other than tubal factor infertility. TFI cases were 
used in all studies and the case population was enlarged in 2006 from 75 to 164 
subjects. The number of study participants was relatively small for genetic analysis. 
In addition, a larger study population would be needed to test the interaction of dif-
ferent candidate genes in the development of TFI. Collection of cases is difficult, a 
factor that restricts sample size. 
In Papers I–III the controls were healthy blood donors from Oulu, Northern Os-
trobothnia, while the cases were collected from Helsinki, Southern Finland. This is 
problematic in candidate gene analysis because of regional heterogeneity and differ-
ent population histories of eastern and western Finns (Lappalainen et al. 2006, Jak-
kula et al. 2008). However, Studies I and III were focused on association between 
genetic markers and immune responses. In Study II TFI cases with different levels 
of tubal pathology were compared and genetic marker association between cases and 
controls was not highlighted. The genotype distribution did not differ significantly 
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between TFI cases and blood donors, with the exception of the IL10 -1082 genotype. 
In addition, the data on genetic associations with LP and cytokine responses were 
parallel, suggesting that these sample cohorts could be combined in analysis of ge-
netic associations with C. trachomatis-specific immune responses. 
In Study III the association between genetic markers and immune responses was 
investigated in subjects in whom a history of past clinically confirmed C. trachoma-
tis infection was not known. Because we wanted to avoid selection bias, subjects 
with viable cell samples were included in the study regardless of their immune re-
sponses to C. trachomatis antigens. Exposure to C. trachomatis infection is similar 
in different genotype groups but genetic differences affect the intensity of immune 
responses. In addition, the studied cytokines IL-10, IFN-γ and TNF are produced by 
innate immunity cells (monocytes, dendritic- and NK-cells) and genetic differences 
may become manifest independently of previous exposure. This setting, which in-
cludes previously unexposed subjects, can, however, bias the results towards low 
lymphocyte reactivity. In vitro studies of Chlamydia immunity have shown that the 
intensities of LP and IFN-γ responses correlate with the amount of circulating mem-
ory T cells (Halme et al. 2000, Kinnunen et al. 2003).   
For the fourth study the control population was enlarged by obtaining samples 
from the Finnish Maternity Cohort (FMC). Samples from pregnant women from the 
Helsinki area were collected to improve the validity of the results. Unfortunately, 
cell samples for LP analysis were not available from the FMC. 
The strengths of our study include accurate TFI case definition by way of laparo-
scopic evaluation (Hubacher et al. 2004) and uniform classification of the degree of 
tubal damage (Rutherford & Jenkins 2002). This is necessary when analyzing ge-
netic associations in connection with disease severity. Moreover, use of a combined 
test of C. trachomatis-specific humoral and CMI in predicting chlamydial TFI 
(Tiitinen et al. 2006) enhances the validity of our study. 
6.2.2 Selected gene polymorphisms and genotyping methods 
The cytokines for candidate gene analysis were selected on the basis of current 
knowledge of their central roles in Chlamydia immunology. The SNPs were selected 
on the basis of information in the literature, and available methodology. 
Candidate gene approach has both benefits and drawbacks. Studies using this ap-
proach tend to have rather high statistical power but are incapable of discovering 
new genes or gene combinations (Amos et al. 2011). The candidate gene association 
studies have also been criticized to yield questionable genotype-phenotype associa-
tions that fail to replicate in independent studies (Chanock et al. 2007). The lack of 
replication may be a result of the complex disease pathogenesis which includes nu-
merous genes and co-existent environmental risk factors. However, reproducibility 
is essential for establishing the credibility of a genotype-phenotype association 
(Zhang et al. 2009). The reliability of candidate gene approach can be increased by 
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selecting SNPs or haplotypes whose functional significance is shown from the basis 
of the effect on in vivo phenotype and on function in vitro (Daly & Day 2001). 
The genetic markers associated with C. trachomatis induced tubal damage could 
be used as diagnostic tools to determine an individual’s risk to develop later compli-
cations. However, the genes and SNPs studied in this dissertation explain only partly 
the genetic variation in disease susceptibility, and in addition to genetics, factors 
such as co-infections and hormonal status affect disease manifestation. Therefore, 
enabling clinical use of such genetic tests would require further studies. 
Leukocyte fraction, blood clots and serum were used as source material for DNA 
isolation. Cells and blood clots were abundant sources of DNA, but, as expected, the 
amounts of DNA were low and its quality worse in serum samples, which contrib-
uted to genotyping failure in some of the samples. Three different methods were 
used for genotyping. Conventional PCR and the use of commercial genotyping trays 
were laborious methods. The results were read independently by two persons. 
MALDI-TOF genotyping used for IL-12-related genes was fast and the analysis was 
run in Oxford. 
In the control population, all studied SNPs were in HWE except for IL10 -1082 
in blood donors. We obtained identical results regarding this genotype using two 
different methods (conventional PCR and a cytokine genotyping tray). This suggests 
that systematic genotyping errors are unlikely. In addition, allele frequencies in the 
IL10 promoter region, and IFNG +874 A/T, TNF -308 A/G and IL6 -174 C/G poly-
morphism data in our controls were similar to data reported by others in healthy 
Finns (Karhukorpi & Karttunen 2001, Wang et al. 2001, Nuolivirta et al. 2009, He-
iskanen et al. 2010, Rantala et al. 2011). 
6.3 Future prospects 
We showed that IL10 promoter polymorphisms are associated with the disease proc-
ess and the intensity of the cell-mediated immune response in C. trachomatis infec-
tion. The immune responses are regulated by a complex network of cytokines and 
our results indicate that individual differences in IFNG, TNF and IL12B genes 
probably also contribute to variation in the clinical outcome of the infection.  
We found an association between the IFNG +874 SNP and the intensity of the C. 
trachomatis-specific cell-mediated immune response, although the differences be-
tween genotype groups were small. However, associations between the studied SNP 
and disease susceptibility or severity were not found. In the future it would be inter-
esting to study other IFNG SNPs and to carry out haplotype analysis as well, be-
cause IFN-γ has a central role in defense against C. trachomatis. Other factors that 
regulate IFN-γ production are also of interest. In this work we found an association 
between the IL12B 1188 SNP and disease susceptibility and severity of tissue dam-
age. In the future, studies dealing with this SNP and IL12B gene expression as well 
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as production of functional IL-12, IL-23 and IL-12p40 cytokines are needed to in-
crease understanding of the mechanisms of pathogenesis. 
The IL12B gene might be also related to the Th17 cell population, which is 
highly proinflammatory and could be involved in pathogenesis. In addition, in-
volvement of regulatory T cells can result in persistent infection and lead to compli-
cations. The involvement of these cell populations in C. trachomatis pathogenetic 
mechanisms would be interesting to study further. 
The use of genome-wide association (GWA) tests could identify new genetic 
variants involved in C. trachomatis pathogenesis. Because the immune response is 
regulated by a complex network of genes, it would be interesting to study also 
epistatic gene-gene interactions in disease pathogenesis. These studies, however, 
would require a larger study population. Gathering a large cohort of women with 
proven Chlamydia-related tubal pathology could be accomplished by collaboration 
between study groups, establishment of research networks and by combining differ-
ent cohorts. 
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7 Conclusions 
In this work we showed that the immunosuppressive cytokine IL-10 and its genetic 
polymorphism IL10 -1082 A/G strongly influence C. trachomatis-induced cytokine 
production. Levels of IL-10 also reflected the production of proinflammatory IFN-γ 
and TNF cytokines as well as the intensity of the LP response. 
We found that the IL10 -1082 AA genotype and TNF -308 A allele were associ-
ated with the severity of tubal damage in women with C. trachomatis-induced TFI. 
The IL10 -1082 AA genotype was associated with low IL-10 production. The TNF -
308 A/G SNP also potentially contributes to the cytokine profile during C. tra-
chomatis infection, but the results were discrepant and the role of this SNP needs to 
be studied further. An association between the IFNG +874 A/T SNP and disease 
severity was not found, but this SNP was associated with the intensity of the LP 
response, and the quantitative secretion of IFN-γ was in line with the LP responses. 
The highest IFN-γ levels and LP responses were found in the subjects with the IFNG 
+874 TT genotype and the lowest levels in those with the AA genotype.  
The IFNG +874 A/T SNP has a cumulative effect together with the IL10 -1082 
A/G SNP on the intensity of C. trachomatis-induced LP responses, although the 
IL10 -1082 A/G SNP clearly had more influence on the LP response. However, the 
central role of IFN-γ in defense is also based on its direct C. trachomatis growth-
limiting actions including induction of tryptophan catabolism and NO production 
(Loomis & Starnbach 2002), which were not evaluated here. 
One of the studied IL-12-related SNPs, IL12B 1188 A/C, was associated with 
TFI and the severity of tubal damage. Carriage of the minor allele C, which has been 
associated with recurrent C. trachomatis infections (Geisler et al. 2010), was associ-
ated with increased risk and severity of C. trachomatis-induced tubal damage. The 
results suggest that IL12B is involved in the disease process, but more data is needed 
to investigate the mechanism behind the genotype association.  
The results of this work increase understanding of disease mechanisms and sup-
port the hypothesis that polymorphisms in several cytokine-coding genes affect the 
risk and severity of TFI by contributing to the cytokine profile and host immune 
response during C. trachomatis infection. Our results suggest that the role of IL-10 
is overwhelming relative to that of proinflammatory cytokines. IL-10 is needed to 
limit tissue pathology. 
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